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Development of the Sustained Release Analgesic Formulations for Rodents and a
Novel In Vitro Model for Parenteral Formulations with the Character of a Level A
IVIVC
Abstract
Laboratory animals are often subjected to various painful surgical procedures such as laparotomy,
thoracotomy or orthopedic procedures as well as non-surgical procedures such as the induction of
arthritis. Any procedure that causes pain in humans is assumed to cause pain in animals too. It is the
ethical obligation of all research personnel to reduce or preferably eliminate pain and distress by using
analgesics. Furthermore, the Institutional Animal Care and Use Committee (IACUC) requires that
appropriate anesthetics and/or analgesics must be used to minimize or eliminate pain and distress for
animals undergoing painful procedures.
The oral administration route is the most convenient delivery method for humans. However, using the oral
administration route for rodents, such as putting an analgesic in the water, runs the risk of inaccurate
dosing and that of degradation due to hydrolysis. Therefore methods for analgesic delivery to rodents are
primarily limited to parenteral rather than oral delivery.
Rodents are the most universally used laboratory animals and are often subjected to research involving
painful procedures. A survey of current literature indicates that buprenorphine is the most widely used
narcotic analgesic for rodents because of its excellent analgesic activity and long duration of action. The
Formulary for Laboratory Animals lists the buprenorphine dose for rats as 0.05 mg/kg (SC, tid, qid). Other
referenced buprenorphine doses for rats vary widely (0.01-0.05 mg/kg, SC/IV, tid, bid) and require multiple
administrations. The recommended dose of buprenorphine for mice following laparotomy is 0.05 to 0.1
mg/kg, subcutaneously (SC) twice a day. Referenced buprenorphine doses for maintaining analgesia in
mice vary widely (0.05-2.5 mg/kg, SC, IV) and repeated administration is required. However, no sustainedrelease analgesic product for rodents was available when we started the project in 2008. Therefore, in
order to reduce the stress of frequent handling and injection as well as improve the well-being of research
animals, the first objective of this project was to develop a long-acting sustained release formulation of
buprenorphine which is capable of maintaining analgesia in rats and mice for 3 to 5 days following a
single subcutaneous administration.
Current United States Pharmacopeia (USP) apparatus for in vitro drug release testing was designed
mainly for oral and transdermal products. In contrast, there are no standard regulatory methods for
parenteral sustained release products at present. As regards to quality control as well as formulation
development purposes, it is still highly desirable to develop a suitable in vitro release model for parenteral
products with the characters of Level A In Vitro-In Vivo Correlation (IVIVC) and elaborate drug release
mechanism. So far there is no successful in vitro dissolution method with the character of Level A IVIVC
exists at present for parenteral oily formations. Only a few publications stated in vitro in vivo correction
for parenteral product, but they were developed from only one particular formulation. In addition, for most
examples in which IVIVC was stated for parenterals, the mathematical models that described the drug
release had not been provided. Therefore, the second objective of this study was to (1) design and
develop a new dissolution model with the character of Level A IVIVC for oily formulations, and (2) develop
a mathematical equation to describe the drug release mechanism from the in vitro model. In general, it is
accepted that the process of development and validation of IVVIC for parenterals could follow the same
principles as modified release (MR) oral products. The principles of FDA IVIVC MR guidance for oral
products were used to develop and validate level A IVIVC for parenterals in this study.
In order to develop sustained release analgesic formulations, nine hydrophobic vehicles, which have been
used in the pharmaceutical products, were selected based on clogP values. Solubility and short-term

stability studies were performed and six vehicles were selected as candidates according to the results.
Since there is no validated in vitro dissolution model for sustained release parenterals at present, a new in
vitro dissolution model were designed based on the in vivo drug absorption mechanism after
subcutaneous injection. In addition, a mathematical equation was proposed and validated to describe the
drug release from this dissolution system. In order to apply this dissolution model to screen the
parenteral formulations in vitro, Level A IVIVC study were performed. In-vivo release of buprenorphine
from two different oily solutions was performed with subcutaneous administration in rats. Loo-Reigelman
method was used to deconvolute plasma data. The mathematical equation, proposed to describe the in
vitro drug release profiles, was also corresponded well with the in-vivo deconvolution data for the tested
formulations (R2 >0.99). Good linear correlations (R2 > 0.99) were also obtained between the mean
percentage of drug absorbed and the mean percentage of drug dissolved. Internal predictability showed
that absolute predictive error (%PE) of Cmax and AUC were 4.9% and 0.9%, 12.6% and 3.4% for the tested
formulations, respectively. External predictability showed that absolute predictive error (%PE) of Cmax
and AUC were 11.9% and 1.1%. This new designed in vitro dissolution apparatus was used to screen six
oily vehicles and TBC was selected. After subcutaneous injection of TBC formulation at the dose of 1.5
mg/Kg in rats, 55% of maximum possible effect (MPE) analgesia can be maintained for 3 days and 20%
MPE for 5 days in conventional tail flick model. The same formulation was tested in mice at the dose of
2.2 mg/Kg which can maintain more than 30% MPE analgesia for 3 days and at the dose of 8.9 mg/Kg
which can keep at least 47% MPE analgesia for 4 days.
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ABSTRACT
Laboratory animals are often subjected to various painful surgical procedures
such as laparotomy, thoracotomy or orthopedic procedures as well as non-surgical
procedures such as the induction of arthritis. Any procedure that causes pain in humans
is assumed to cause pain in animals too. It is the ethical obligation of all research
personnel to reduce or preferably eliminate pain and distress by using analgesics.
Furthermore, the Institutional Animal Care and Use Committee (IACUC) requires that
appropriate anesthetics and/or analgesics must be used to minimize or eliminate pain and
distress for animals undergoing painful procedures.
The oral administration route is the most convenient delivery method for humans.
However, using the oral administration route for rodents, such as putting an analgesic in
the water, runs the risk of inaccurate dosing and that of degradation due to hydrolysis.
Therefore methods for analgesic delivery to rodents are primarily limited to parenteral
rather than oral delivery.
Rodents are the most universally used laboratory animals and are often subjected
to research involving painful procedures. A survey of current literature indicates that
buprenorphine is the most widely used narcotic analgesic for rodents because of its
excellent analgesic activity and long duration of action. The Formulary for Laboratory
Animals lists the buprenorphine dose for rats as 0.05 mg/kg (SC, tid, qid). Other
referenced buprenorphine doses for rats vary widely (0.01-0.05 mg/kg, SC/IV, tid, bid)
and require multiple administrations. The recommended dose of buprenorphine for mice
following laparotomy is 0.05 to 0.1 mg/kg, subcutaneously (SC) twice a day. Referenced
buprenorphine doses for maintaining analgesia in mice vary widely (0.05-2.5 mg/kg, SC,
IV) and repeated administration is required. However, no sustained-release analgesic
product for rodents was available when we started the project in 2008. Therefore, in order
to reduce the stress of frequent handling and injection as well as improve the well-being
of research animals, the first objective of this project was to develop a long-acting
sustained release formulation of buprenorphine which is capable of maintaining analgesia
in rats and mice for 3 to 5 days following a single subcutaneous administration.
Current United States Pharmacopeia (USP) apparatus for in vitro drug release
testing was designed mainly for oral and transdermal products. In contrast, there are no
standard regulatory methods for parenteral sustained release products at present. As
regards to quality control as well as formulation development purposes, it is still highly
desirable to develop a suitable in vitro release model for parenteral products with the
characters of Level A In Vitro-In Vivo Correlation (IVIVC) and elaborate drug release
mechanism. So far there is no successful in vitro dissolution method with the character of
Level A IVIVC exists at present for parenteral oily formations. Only a few publications
stated in vitro in vivo correction for parenteral product, but they were developed from
only one particular formulation. In addition, for most examples in which IVIVC was
stated for parenterals, the mathematical models that described the drug release had not
been provided. Therefore, the second objective of this study was to (1) design and
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develop a new dissolution model with the character of Level A IVIVC for oily
formulations, and (2) develop a mathematical equation to describe the drug release
mechanism from the in vitro model. In general, it is accepted that the process of
development and validation of IVVIC for parenterals could follow the same principles as
modified release (MR) oral products. The principles of FDA IVIVC MR guidance for
oral products were used to develop and validate level A IVIVC for parenterals in this
study.
In order to develop sustained release analgesic formulations, nine hydrophobic
vehicles, which have been used in the pharmaceutical products, were selected based on
clogP values. Solubility and short-term stability studies were performed and six vehicles
were selected as candidates according to the results. Since there is no validated in vitro
dissolution model for sustained release parenterals at present, a new in vitro dissolution
model were designed based on the in vivo drug absorption mechanism after subcutaneous
injection. In addition, a mathematical equation was proposed and validated to describe
the drug release from this dissolution system. In order to apply this dissolution model to
screen the parenteral formulations in vitro, Level A IVIVC study were performed. Invivo release of buprenorphine from two different oily solutions was performed after
subcutaneous administration in rats. Loo-Reigelman method was used to deconvolute
plasma data. The mathematical equation, proposed to describe the in vitro drug release
profiles, was also corresponded well with the in-vivo deconvolution data for the tested
formulations (R2>0.99). Good linear correlations (R2 > 0.99) were also obtained between
the mean fraction of drug absorbed and the mean percentage of drug dissolved. Internal
predictability showed that absolute predictive error (%PE) of Cmax and AUC were 4.9%
and 0.9%, 12.6% and 3.4% for the tested formulations, respectively. External
predictability showed that absolute predictive error (%PE) of Cmax and AUC were
11.9% and 1.1%. This new designed in vitro dissolution apparatus was used to screen six
oily vehicles and TBC was selected. After subcutaneous injection of TBC formulation at
the dose of 1.5 mg/Kg in rats, 55% of maximum possible effect (MPE) analgesia can be
maintained for 3 days and 20% MPE for 5 days in conventional tail flick model. The
same formulation was tested in mice at the dose of 2.2 mg/Kg which can maintain more
than 30% MPE analgesia for 3 days and at the dose of 8.9 mg/Kg which can keep at least
47% MPE analgesia for 4 days.
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CHAPTER 1.
1.1.
1.1.1.

INTRODUCTION

Buprenorphine

Description

Buprenorphine is a μ-opioid receptor partial agonist and a κ-opioid receptor
antagonist listed in Schedule III of the Controlled Substances Act.1 It is a semi-synthetic
opioid derived from thebaine.2 It was first marketed in the 1980s by Reckitt & Colman
(now Reckitt Benckiser) as an analgesic. The chemical structure of buprenorphine
(Figure 1-1) resembles that of morphine, but it contains a cyclopropylmethyl group on
the nitrogen atom. Buprenorphine base is a white or almost white powder and is slightly
soluble in water, freely soluble in acetone, soluble in methanol and ether and slightly
soluble in cyclohexane. The pKa values of buprenorphine are 8.5 and 10.0.3
1.1.2.

Current commercial dosage forms of buprenorphine in human

Current commercially marketed products of buprenorphine in humans include
Buprenex injection, Suboxone tablet, Subutex tablet, Suboxone film, Transtec ER patch,
Butrans ER patch, Norspan ER patch and Probuphine implant (Table 1-1).
Buprenex1 is a parenteral opioid analgesic intended for intravenous or
intramuscular administration for the relief of moderate to severe pain. Each mL of
Buprenex injection contains 0.324 mg buprenorphine hydrochloride (equivalent to 0.3 mg
buprenorphine), 50 mg anhydrous dextrose, water for injection and HCl to adjust pH.
Both Subutex1 tablet and Suboxone1 tablet are indicated for the treatment of
opioid dependence by sublingual administration because of the poor oral bioavailability
of buprenorphine. Subutex contains only buprenorphine hydrochloride with other
excipients, lactose, mannitol, cornstarch, povidone K30, citric acid, sodium citrate and
magnesium stearate. Suboxone contains an additional ingredient, naloxone, with other
excipients, including lactose, mannitol, cornstarch, povidone K30, citric acid, sodium
citrate, FD&C Yellow No.6 color, magnesium stearate, acesulfame K sweetener and a
lemon/lime flavor. Naloxone is an opioid antagonist and is used in Suboxone tablet to
deter the abuse of tablets by intravenous injection. Subutex and Suboxone are both
available in 2 mg and 8 mg sublingual dosages.
Suboxone1 is also approved by FDA on August 30, 2010 as a sublingual film in
both the 2 mg/0.5 mg and 8 mg/2 mg dosages (buprenorphine/Naloxone). Reckitt
Benckiser Pharmaceuticals claimed that the film has some advantages over the traditional
tablet including dissolving faster, better taste, adhering to the oral mucosa under the
tongue and preventing it from being swallowed or falling out.

1

Molecular weight:
Empirical formula:
CAS Number:
Chemical name:

467.6
C29H41NO4.
52485-79-7
(2s)-2-[17-cyclopropylmethyl)-4, 5α-epoxy-3-hydroxy-6-methoxy6α, 14 -ethano-14α -morphinan-7α -yl]-3,3-dimethylbutan-2-ol

Figure 1-1. Chemical structure, molecular weight, empirical formula, CAS
Number and chemical name of buprenorphine.
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Table 1-1.
Trade
Name
Buprenex
(US)

Commercially available buprenorphine products.
Dosage
Form/Route

Strength

Injection Solution 0.3 mg base/mL
/IV or IM

Suboxone
(US)

Tablet/Sublingual

2mg/0.5mg,
8mg/2mg
(buprenorphine
HCl / Naloxone
HCl)

Suboxone
(US)

Film/Sublingual

2 mg/0.5 mg,
8 mg/2 mg
(buprenorphine /
Naloxone)

Subutex
(US)

Tablet/Sublingual

2 mg; 8 mg (base)

Approval
Date

Ingredients

Sponsor

buprenorphine HCl (0.324 mg/mL),
anhydrous dextrose (50 mg/mL),
water for injection, HCl (adjust pH)

Reckitt Benkiser
Pharmaceuticals,
Inc.

December 29,
1981

NA
NA
NA
buprenorphine HCl, Naloxone HCl,
lactose, mannitol, cornstarch,
povidone K30, citric acid, sodium
citrate, FD&C Yellow No.6 color,
magnesium stearate, Acesulfame K
sweetener and a lemon lime flavor.
buprenorphine HCl, naloxone HCl
dihydrate, polyethylene oxide,
hydroxypropyl methylcellulose,
maltitol, acesulfame potassium, lime
flavor, citric acid, sodium citrate,
FD&C yellow #6, and white ink
buprenorphine HCl, lactose,
mannitol, cornstarch, povidone K30,
citric acid, sodium citrate and
magnesium stearate.
NA

Hospira (generic)
Bedford (generic)
Luitpold (generic)
Reckitt Benkiser
Pharmaceuticals,
Inc.

June 3, 1996
March 2, 2005
March 27, 2007
October 8,
2002

Reckitt Benkiser
Pharmaceuticals,
Inc.

August 30,
2010

Reckitt Benkiser
Pharmaceuticals,
Inc.

October 8,
2002

Roxane
Laboratories , Inc.
(generic)
Barr Laboratories,
Inc. (generic)
EthyPharm
(generic)

October 8,
2009

NA
NA
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May 7, 2010
September 24,
2010

Table 1-1.
Trade
Name
Transtec
(US)
Butrans
(US)
Norspan
(Australia )

Probuphine

(Continued).
Dosage
Form/Route
ER patch (4-day)
/Transdermal
ER patch (7-day)
/Transdermal
ER patch (7-day)
/Transdermal

Strength

Ingredients

35, 52.5 and 70
NA
mcg/hr
5, 10 and 20 mcg/hr NA

5, 10 and 20 mcg/hr buprenorphine base, levulinic acid,
oleyl oleate, povidone, Duro Tak
387-2051, Duro Tak 387-2054 and
polyethylene terephthalate
Implant (6-month) NA
NA
/subcutaneous
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Sponsor

Approval
Date

Grunenthal

2001

Purdue Pharma,
LLC
Mundipharma
and Grunenthal

June 30, 2010

Titan
Pharmaceuticals,
Inc.

July 2008
(opioid
addiction, phase
III; chronic pain,
phase I)

April 4, 2005

The transdermal buprenorphine patch, Transtec, was first launched in
Switzerland and Germany in 2001 and is now marketed all over Europe.4 It is used to
treat moderate to severe cancer pain and severe pain which does not respond to nonopioid analgesics. It is not suitable for the treatment of acute pain. Butrans is a 7-day
patch for the relief of moderate to severe pain in patients requiring continuous, aroundthe-clock opioid treatment for an extended period of time. It was approved by US FDA
on June 30, 2010 and marked by Purdue Pharma with the strengths of 5, 10 and
20 mcg/hr. Norspan is also a 7-day analgesic patch but available in Austrilia.5 It is
indicated for the treatment of moderate chronic pain not responding to non-opioids, dosed
in 5, 10 or 20 mcg/hr patches.
Probuphine6 is a novel subcutaneous implant to deliver six months of
buprenorphine. Titan Pharmaceuticals announced positive, statistically significant results
from its randomized, double-blind, placebo controlled, multi-center Phase III clinical trial
of Probuphine for the potential treatment of opioid addiction in July 2008. The phase I
study of Probuphine on treatment of chronic pain is still going on.
1.1.3.

Pharmacology of buprenorphine

Buprenorphine is usually described as a “-receptor partial agonist”, “mixed
opioid receptor agonist-antagonist”, “high affinity mu agonist/kappa antagonist”, or
“narcotic antagonist analgesic”.7 It is used clinically for pain management and the
treatment of opioid dependency. The exact mechanisms of action of buprenorphine are
not fully understood. Antinociceptive effect of buprenorphine is primarily mediated by
the μ-opioid receptor. The data shows that buprenorphine can attenuate or abolish the
action of other full agonists, such as morphine, and produce a submaximal
antinociceptive effect.8-10 Therefore buprenorphine is usually accepted as a “partial” μopioid receptor agonist.11-15 It is also a κ-receptor antagonist.10,16 In addition, recent
discovery shows that buprenorphine has the affinity to delta and ORL-1 receptor17 (Table
1-2).
Buprenorphine has a unique bell-shaped dose-response curve for
antinociception.2,18-20 The analgesia response of buprenorphine in rat tails warm water
study did not grow with increased dose. The dose for the highest response was found at 3
mg/kg.20 On the contrary, dose-response curve decreased with increasing dose at high
dose range. The exact mechanisms are not fully understood. The possible mechanisms
could be partial agonism at the  opioid receptor and, in some cases, antagonism at the
kappa or delta opioid receptor.17 Recent data17 suggest that the action of buprenorphine at
the ORL-1 receptor could be responsible for the ceiling effect and for the bell-shaped
dose-response curves observed after administration of the drug in the radiant heat tail
flick assay. The antinociceptive effect of buprenorphine is attenuated by the ability of the
drug to activate the ORL-1 receptor in opioid receptor knockout mice.
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Table 1-2.
Apparent Ki values of buprenorphine for the various members of the
opioid receptor family.
Animals
Rat Brain21
Monkey Brain22

Mu
0.08 ± 0.02
0.08 ± 0.01

Kappa
0.11 ± 0.05
0.44 ± 0.08

Delta
0.42 ± 0.04
0.82 ± 0.11

ORL-1
285 ± 30
not determined

Data are presented as mean ± SEM (nM).
Source: Lutfy K, Cowan A 2004. Buprenorphine: A unique drug with complex
pharmacology. Curr Neuropharmacol 2(4):395-402. Reprinted with permission.
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1.1.4.

Pharmacokinetics of buprenorphine

1.1.4.1. Pharmacokinetic parameters
Ohtani et al.2,23 published the pharmacokinetic parameters of buprenorphine in
rats by intravenous administration at doses of 0.06 mg/kg and 0.6 mg/kg, and claimed
that the plasma concentration of buprenorphine declined biexponentially after
intravenous administration and the mean t1/2 (elimination half-life), CL (clearance), Vss
(volume distribution at steady-state), and MRT (mean residence time) values for
buprenorphine were 2.8 hr, 1.4 L/hr/kg, 4.2 L/kg, and 3.0 hr at the dose of 0.6 mg/kg and
2.4 hr, 1.32 L/hr/kg, 3.5 L/kg, and 2.8 hr at the dose of 0.06 mg/kg, respectively. Gopal et
al.24 reported the pharmacokinetic parameters of buprenorphine in rats after receiving a
single intravenous bolus dose of 0.1, 0.3, 1, 3, 10 or 30 mg/kg. The mean t1/2, CL, Vss,
and MRT values for buprenorphine were 4.75-5.28 hr, 2.7-6.1 L/hr/kg, 8.37-18.2 L/kg,
and 3.02-3.83 hr, respectively. Yu et al.25 indicated that the pharmacokinetic values of t1/2,
CL, and Vss were 2.9 hr, 4.3 L/hr/kg, 6.5 L/kg, respectively, after intravenous
administration of the buprenorphine solution at the dose of 2.4 mg/kg in the mouse.
1.1.4.2. Absorption distribution metabolism and excretion (ADME)
Due to the extensive first-pass effect, the bioavailability of buprenorphine in
humans following oral administration is approximately 10%.26 The systemic
bioavailability of buprenorphine varies by various routes of administration in rats. After
single doses of 0.2 mg/kg buprenorphine solution, the systemic bioavailability of
buprenorphine has been studied in female rats. The mean bioavailabilities were
intravenous, 98%; intrarectal, 54%; intrahepatoportal, 49%; sublingual, 13%; and
intraduodenal, 9.7%, relative to the 100% bioavailability from the intra arterial route.27
After an intravenous dose of 0.2 mg/kg28,29 buprenorphine in the rats, high levels
of buprenorphine were found in the lung, heart, kidney and liver, and buprenorphine level
in the brain was higher than that in the plasma. Two metabolic pathways,2 N-dealkylation
by CYP3A4 and glucuronidation, were well documented in rat, rabbit, dog, baboon, and
rhesus monkey,15 and could lead to the three major metabolites of buprenorphine,
buprenorphine-3-glucuronide; N-dealkylbupurenorphine (norbuprenorphine) and
norbuprenorphine-3-glucuronide. The primary metabolite is buprenorphine-glucuronide
and the rest are norbuprenorphine and norbuprenorphine-glucuronide. The conjugated
metabolites, buprenorphine-glucuronide and norbuprenorphine-glucuronide, are mostly
excreted in bile in rats.23 Independent of species, buprenorphine is mainly excreted
through the bile23,30 and eliminated in the faeces, and a small amount of metabolites are
excreted through the urine by urinary excretion.2 Enterohepatic circulation of
buprenorphine was found in rats, dogs, monkeys and human.23,30,31 The conjugated
metabolites, buprenorphine-glucuronide and norbuprenorphine-glucuronide, in the bile
could be absorbed after the return of the parent drugs, buprenorphine and
norbuprenorphine, to the intestinal tract.2
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1.2.

Injectable Analgesics for Rodents

Current injectable analgesic for rodents can be divided into two groups: opioid
and non-steroidal anti-inflammatory drug (NSAID) analgesics. The dose, administration
route and formulation of analgesics for rodents are listed in Table 1-3.
1.2.1.

Opioid injectable analgesics for rodents

Opioid analgesics are the derivatives of opiates and usually used in moderate to
severe types of pain for rodents.32 These types of analgesics used in rodents can be
classified as agonists, partial agonists, and agonist/antagonist. 33 Agents, such as
morphine, codeine, and propoxyphene, are agonists which bind to central nervous system
opiate μ-receptors to produce analgesia and reduce the perception of pain. Agents, such
as buprenorphine, are partial agonists of μ-receptor, but the maximal analgesia produced
is less than full agonist. Agents, such as butorphanol and nalbuphine, are agonistantagonists. These drugs are agonist of some opioid receptors, but act as antagonist at
other opioid receptors.
1.2.1.1. Buprenorphine
Buprenorphine is currently considered as the standard opioid analgesic for rats
and mice.34 It is the most commonly used and reported35 analgesic for rodents. It is the
partial agonist for the μ-receptor and has a relatively long duration of analgesic action (8
to 12 hours). Buprenorphine is used as an analgesic for pain relief after surgical
procedures and is considered to be approximately 30 times stronger than morphine.
Buprenorphine is well absorbed after intramuscular (IM) and subcutaneous (SC)
injection, and is metabolized in the liver. In rats, the drug concentrates in the liver, brain,
gastrointestinal tract and placenta. It is then excreted in urine, and via breast milk. It is
therefore not recommended to be given to pregnant or lactating rats.36
The commercial product of buprenorphine is Buprenex. Each mL of Buprenex
contains 0.324 mg buprenorphine hydrochloride (equivalent to 0.3 mg buprenorphine),
50 mg anhydrous dextrose, water for injection and HCI to adjust pH.
1.2.1.2. Morphine
Morphine is a highly potent opiate analgesic drug which interacts predominantly
with the μ-opioid receptor. In clinical practice, morphine is regarded as the gold standard
of analgesics used to relieve severe or agonizing pain. The primary side effect of
morphine for rodents is respiratory depression. Fortunately, the effects are species
specific. For example, morphine can produce analgesia without respiratory depression in
the hamster.44
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Table 1-3.

Recommended analgesics for rats and mice.
Administration
Frequency
Route

Drug

Species

Dose

Buprenorphine

Rats

0.01-0.1 mg/kg 37-39

SC37-39, IV37,38

q 6-12 hr37-39

Mice

0.05-0.1 mg/kg 37,39,40

SC37,39,40, IV37

q 12 hr37,40
q 3-6 hr39

Rats

2 mg/kg 38,39

SC38,39

q 4-6 hr38,39

Mice

1-5 mg/kg39,40

SC39,40

q 6 hr40
q 8-12 hr39

Rats
Mice
Rats

SC37, 41
SC37
39,42
SC , IM42

sid37
sid37
q 2-4 hr39,42

SC39,42, IM42

q 2-4 hr39,42

Rats

5 mg/kg37
5 mg/kg37
2.5-5 mg/kg39
10 mg/kg42
2.5 mg/kg 39
10 mg/kg42
2.5-5 mg/kg37,39

SC37,39, IM37

sid37, bid39

Mice

1-5 mg/kg37

SC37

sid37

Rats

1-2 mg/kg39,43

SC39,43

sid39,43

Mice

1 mg/kg39

SC39

sid39

Butorphanol

Ketoprofen
Morphine

Mice
Carprofen

Meloxicam

Q: every.
Sid: once daily.
Bid: twice daily.
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Formulation of Commercial Product
Buprenorphine hydrochloride (0.324 mg/mL, equivalent to 0.3
mg buprenorphine per mL);
Anhydrous dextrose (50 mg/mL);
Water;
HCl (adjust pH).
Butorphanol tartrate (1 or 2 mg/mL);
Citric acid (3.3 mg/mL);
Sodium citrate (6.4 mg/mL);
NaCl (6.4 mg/mL);
Benzethonium chloride (0.1 mg/mL, in multiple dose vial only).
Ketoprofen (100 mg/mL);
L-arginine (72 mg);
Benzyl alcohol (1%);
Citric acid (adjust pH).
Morphine sulfate pentahydrate (0.5 or 1 mg/mL);
NaCl (9 mg/mL);
NaOH and/or HCl (adjust pH).
Carprofen (50.0 mg/mL);
Arginine (30.0 mg/mL);
Glycocholic acid (88.5 mg/mL);
Benzyl alcohol (10.0 mg/mL);
Meloxicam (5.0 mg/mL);
Alcohol (15%);
Glycofurol (10%);
Poloxamer 188 (5%);
NaCl (0.6%);

Lecithin (169.0 mg/mL);
NaOH (6.17 mg/mL);
NaOH and/or HCl (adjust pH);
Water.
Glycine (0.5%);
Meglumine (0.3%);
Water;
NaOH and HCl (adjust pH)

Each mL of commercial available morphine sulfate injection contains morphine
sulfate pentahydrate 0.5 mg or 1 mg and sodium chloride 9 mg. It may also contain
sodium hydroxide and/or hydrochloric acid for pH adjustment.45
1.2.1.3. Butorphanol
Butorphanol is a synthetic opiate agonist-antagonist that is structurally related to
morphine. Butorphanol binds to opiate receptors at sites in the central nervous system and
alters perception and response to pain.46 It is more potent than morphine, but unlike
morphine it possesses less cardiovascular effects, and respiratory center sensitivity.
Butorphanol Tartrate (Torbutrol, Torbugesic, Stadol) is available as Torbutrol
injectable (0.5 mg/mL in 10 mL vials), Torbugesic injectable (10 mg/mL in 50 mL vials)
and Stadol injectable (1 mg/mL and 2 mg/mL). Stadol Injection is a sterile, parenteral,
aqueous solution of butorphanol tartrate for intravenous or intramuscular administration.
In addition to 1 or 2 mg of butorphanol tartrate, each mL of solution contains 3.3 mg of
citric acid, 6.4 mg sodium citrate, and 6.4 mg sodium chloride, and 0.1 mg benzethonium
chloride (in multiple dose vial only) as a preservative.
1.2.2.

NSAID injectable analgesics for rodents

Non-steroidal anti-inflammatory drugs (NSAIDs) can be classified as traditional
cyclooxygenases (COX) inhibitor and COX-2 inhibitor. Traditional NSAIDs have been
used more for mild pain and anti-inflammation activities than for chronic pain.47 While
2nd generation NSAIDs can alleviate acute pain, such as that produced by surgery48 and
have significant analgesic properties which overlap with the activity of the opioids.47
First generation of NSAIDs, such as Aspirin, can decrease the production of
prostaglandin by inhibiting COX, which reduces pain and also inflammation. Research
suggested that most of the adverse effects of NSAIDs were regulated by blocking the
COX-1 enzyme, while the analgesic effects were mediated by the COX-2 enzyme. Thus
the 2nd generation COX2 inhibitors, such as carprofen and meloxicam, were developed to
inhibit only the COX-2 enzyme.
NSAIDs can be administered via IM, SC or PO. The metabolism and excretion of
NSAIDs vary widely among agents and species. In general, the NSAIDS are metabolized
by the liver and excreted by the kidneys.47
1.2.2.1. Carprofen
Carprofen also belongs to NSAID which is a selective COX-2 inhibitor. It is used
in the treatment of pain for either short term or long term use. It can also be used as an
alternative to opioid based post-operative pain. Usually carprofen is used to treat post-
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operative, injury-related, and chronic (e.g., cancer-related) pain in dogs and cats as well
as rabbits, coatis and many small mammals.49 Carprofen for animals is one of the most
reliable and useful active principles available to veterinarians for treating animals in pain.
It has a dual mode of action: -receptor agonism and mono-amine reuptake inhibition,
which produces mild anti-anxiety results.50 The advantage of this drug is less respiratory
and cardiovascular side effects than the opioids, and longer acting time. Recommended
dose of carprofen for rats is 5-10 mg/kg orally51 or 5-10 mg/kg SC.52
The drug is metabolized in the liver and primarily eliminated in feces with a small
percentage being eliminated in the urine. There is some enterohepatic recycling of the
drug.
Carprofen is marketed under 75 trade names49 around the world. Carprofen is
available as Tramadol hydrochloride injection (50mg/1ml and 100mg/2ml),53 which is
not currently marketed in the US for human use, but it is still available in other
countries.54 Each mL of carprofen Injectable contains 50.0 mg carprofen, 30.0 mg
arginine, 88.5 mg glycocholic acid, 169.0 mg lecithin, 10.0 mg benzyl alcohol, 6.17 mg
sodium hydroxide, with additional sodium hydroxide and hydrochloric acid as needed to
adjust pH, and water for injection.55
1.2.2.2. Meloxicam
Meloxicam is also a NSAID and shows a more selective inhibition of COX-2. It is
used to treat mild to moderate to severe pain in rats. Meloxicam is relatively expensive
and thus may not be practical for everyday use. A dose of 1-2 mg/kg orally or
subcutaneously once a day for rats has been given.56 Both injectable and oral
formulations of meloxicam have been licensed for use in dogs and injectable ones for use
in cats since 1980’s.
The commercial product of Meloxicam is Metacam. Each mL of this sterile
product for injection contains meloxicam 5.0 mg, alcohol 15%, glycofurol 10%,
poloxamer 188 5%, sodium chloride 0.6%, glycine 0.5%, and meglumine 0.3%, in water
for injection, pH adjusted with sodium hydroxide and hydrochloric acid.57
1.2.2.3. Ketoprofen
Ketoprofen is a propionic acid derivative.58 It is a NSAID which inhibits both the
cyclooxygenase and lypoxygenase pathways of arachidonic acid breakdown. It is a
potent, non-narcotic analgesic and anti-pyretic agent.59
Ketoprofen is available as Anafen Injection (100 mg/mL). Each mL contains 100
mg ketoprofen, 72 mg L-arginine, 1% benzyl alcohol as a preservative and suitable citric
acid to adjust pH.60
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1.3.

Sustained Release Analgesic Formulations in Animals

Several sustained release analgesic formulations have been studied in animals.
Transdermal fentanyl patches have been studied in cats61, dogs61,62, sheep63,and rabbits64
for up to 72 hours. Liposomal formulations of opioid analgesics have been tested in mice
and rats. Administration of liposomal oxymorphone at the time of surgery improved
postsurgical recovery in mice.34 Liposome-encapsulated oxymorphone was found to
provide prolonged relief of postsurgical visceral pain for at least 48 hr in a rat short-gut
syndrome model.65 Liposome-encapsulated oxymorphone or morphine was effective in
preventing hyperalgesia in rat neuropathic pain model for up to seven days.66 Liposomeencapsulated opioid analgesic, hydromorphone, was tested in a chronic constriction
injury thermal hyperalgesia rat model of neuropathic pain, and found that preemptive
injection of liposome-encapsulated hydromorphone prevented hyperalgesia in this model
for five days.67 However, these tested sustained release analgesic patches or liposomal
formulations were not practical and economic to rodents. In 2011, commercially
available buprenorphine HCl sustained release product was announced by ZooPharm
(Fort Collins, CO). The formulation is composed of a biocompatible organic solvent and
biodegradable copolymer with an average molecular weight of approximately 5500 Da
and a 50:50 molar ratio of DL-lactide to ε-caprolactone. It was claimed that the
formulation could provide sustained release of buprenorphine for 72 hours after
subcutaneous administration.68 The disadvantages of this polymeric delivery system are
potential irritation and relatively expensive considering the large amount of rodents used
in research.
1.4.

In Vitro Dissolution Model for Parenteral Dosage Forms

So far there are no standard regulatory methods for parenteral sustained release
products at present.69,70 Over the past decade, several methods have been attempted to
describe drug release from parenteral products and the current in vitro release methods for
parenterals might be divided into four broad categories (Figure 1-2): sample-andseparate (SS),69,70 continuous flow (CF),69,70 ultrafiltration,70 and dialysis techniques
including rotating dialysis,71 dialysis sac,70 and microdialysis.70 The advantages and
disadvantages of each method were discussed by Diane J. Burgess70 and Claus Larsen.69
Sample-and-separate method69 is a closed system and generally used to test
microsphere based or gel formulations. The formulation is introduced into a vessel/vial
containing the release medium. The experiment is then conducted at constant temperature
with agitation. At predetermined time intervals, samples are taken from the supernatant
and analyzed for released drug content. After sampling, same volume of fresh medium is
added to the system to maintain a constant volume.
USP (United States Pharmacopeia) apparatus 4 is the commonly used continuous
flow method69,72 for microparticulate systems. The microparticulate formulation is
usually placed in the release cell and the dissolution medium is pumped into the cell at
constant flow rate. The drug content can be analyzed directly from the effluent and
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Figure 1-2.

Schematic illustration of different in vitro dissolution methods for parenterals.

(A) Sample and separation method (S-S).
(B1) Closed-loop and (B2) open-loop configuration for flow-through cell apparatus.
(C) Ultrafiltration technique.
(D1) Dialysis membrane-based technique (DMB).
(D2) Rotating dialysis cell model.
(D3) Reversed dialysis sac technique.
(D4) Microdialysis sampling technique.
Source: Larsen C, Larsen SW, Jensen H, Yaghmur A, Ostergaard J 2009. Role of in vitro release models in formulation development
and quality control of parenteral depots. Expert Opin Drug Deliv 6(12):1283-1295. Reprinted with permission.
Source: Krishna R, Yu L 2008. Biopharmaceutics Applications in Drug Development.336-358. Reprinted with permission.
Source: Schultz K, Mollgaard B, Frokjaer S, Larsen C 1997. Rotating dialysis cell as in vitro release method for oily parenteral depot
solutions. Int J Pharm 157(2):163-169. Reprinted with permission.
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medium can be recirculated into the system, or monitored after collecting the samples.
Ultrafiltration73 is a membrane filtration technique. This separation technique is
usually used to purify and concentrate macromolecular solutions, especially protein
solutions. Low molecular weight solutes pass through the semipermeable membrane and
suspended solids and solutes of high molecular weight are retained. In order to solve the
difficulty of separation of the delivery system from the media, ultrafiltration70,74 method
is proposed for the evaluation of drug release profile from colloidal carriers such as
submicron emulsions and nanoparticles at low pressure. It was claimed that ultrafiltration
method at low pressure was versatile, sensitive and capable of distinguishing between
different kinetic behaviors.
The dialysis membrane-based (DMB) method most often can be referred to as
two-compartment release model. It usually consists of a small donor compartment and a
large acceptor compartment separated by the dialysis membrane. Among the DMB
methods, (1) rotating dialysis cell model71 is well characterized and consists of a small
donor compartment (5-8 mL) and a large acceptor compartment (1000 mL) separated by
a dialysis membrane. Lipophilic (oily) solutions, aqueous suspensions, microspheres and
liposomes have been tested in this model and the drug release mechanism has been well
characterized. Also the in vitro and in vivo correlation has been established for a
particular formulation in this model. (2) Float A Lyzer69 is the commercially available
dialysis membrane-based model which works with the gentle agitation in the donor
compartment, resulting in lower drug transport rates. (3) In dialysis sac70,75 system,
dispersed phase (e.g. emulsion) is directly placed into the large donor chamber with the
stirred sink solution and the sacs contain only media. At predetermined time intervals,
dialysis bags were withdrawn for drug content analysis. (4) Microdialysis technique76
usually is used for continuous measurement of free, unbound analyte concentrations in
the extracellular fluid of virtually any tissue. The microdialysis probe consists of a shaft
with a semipermeable hollow fiber membrane at its tip, which is connected to inlet and
outlet tubing. The microdialysis system used for parenterals70,75 consists of the syringe
pump, microdialysis probe, 40-mesh screen and a magnetic stirrer system. The implant
was usually placed on the screen, and the microdialysis probe was placed at a fixed
distance from the implant. The release medium was constantly stirred with the aid of a
magnetic stirrer at the bottom of the reservoir. At predetermined time intervals, the
samples were collected directly into the autosampler injection vials and drug content was
further determined.
1.5.
1.5.1.

IVIVC

Definition

An in vitro-in vivo correlation (IVIVC) has been defined by the Food and Drug
Administration (FDA) as "a predictive mathematical model describing the relationship
between an in vitro property (usually the extent or rate of drug release) and a relevant in
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vivo response (e.g. plasma concentration or amount of drug absorbed)".77 The United
States Pharmacopoeia (USP) also defines IVIVC as "the establishment of a relationship
between a biological property, or a parameter derived from a biological property
produced by a dosage form, and a physico-chemical characteristic of the same dosage
form".78
1.5.2.

Categories

According to the FDA, IVIVC are categorized as Levels A, B, C and Multiple C.
The classification of correlation level is based upon the ability of predictive mathematical
model to correlate the entire plasma drug concentration time curve or other important
pharmacokinetic parameters with the in vitro dissolution profile or parameters. According
to FDA guidance, (1) Level A correlation is “a predictive mathematical model for the
relationship between the entire in vitro dissolution/release time course and the entire in
vivo response time course (e.g., the time course of plasma drug concentration or amount
of drug absorbed)”.78 Level A correlation is general linear and represents a point-to-point
relationship between in vitro dissolution and the in vivo input rate of the drug from the
dosage form. The key of the correlation is point-to-point correlation and therefore the in
vitro dissolution and in vivo input rate curves can share the same mathematical equation
to describe the drug release behavior. (2) Level B correlation is “a predictive
mathematical model for the relationship between summary parameters that characterize
the in vitro and in vivo time courses (e.g., models that relate the mean in vitro dissolution
time to the mean in vivo dissolution time, the mean in vitro dissolution time to the mean
residence time in vivo, or the in vitro dissolution rate constant to the absorption rate
constant)”.78 A Level B correlation utilizes all of the in vitro and in vivo data, but it is not
considered to be a point-to-point correlation since it does not reflect the entire in vivo
plasma level curve. Since Level B correlation cannot uniquely reflect the actual in vivo
plasma level curve, it has less application than Level A correlation. It is least useful for
regulatory purposes. (3) Level C correlation is “a predictive mathematical model of the
relationship between the amount dissolved in vitro at a particular time (or the time
required for in vitro dissolution of a fixed percent of the dose, e.g., T50%) and a
summary parameter that characterizes the in vivo time course”.78 Level C represents a
single point correlation between one dissolution time point (e.g., T50%, T90%) and one
important pharmacokinetic parameter (e.g., AUC, Cmax or Tmax). Level C correlations can
be useful in the early stages of formulation development when pilot formulations are
being selected. (4) A multiple Level C correlation represents relationship between the
amount of drug dissolved at several time points of the dissolution profile and one or
several pharmacokinetic parameters of interest. Multiple Level C correlations can be as
useful as Level A correlations. But if a multiple Level C correlation is possible, then a
Level A correlation is also likely and is preferred.78
Level A correlation is the most informative and useful for waiver of an in vivo
bioequivalence study (biowaiver). Level B and C IVIVCs have been applied in
formulation development, optimizing manufacturing processes, quality control processes,
and characterizing the release patterns of newly formulated IR and modified-release
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products relative to the references.79 A multiple Level C correlation may be used to
justify a biowaiver by establishment of the correlation over the entire dissolution profile
with one or more pharmacokinetic parameters of interest.
1.5.3.

Evaluation

The objective of developing IVIVC is to establish a predictive mathematical
model describing the relationship between an in vitro property and a relevant in vivo
response.78 It is recommended by FDA that the IVIVC relationship should be
demonstrated consistently with two or more formulations with different release rates to
result in corresponding differences in absorption profiles. The evaluation of IVIVC
should be able to demonstrate that predictability of in vivo performance of a drug product
from its in vitro dissolution profile. Generally, Level A IVIVC validation can be assessed
by prediction of plasma profiles or AUC from in vitro dissolution data using the
developed IVIVC.
The objective of IVIVC evaluation is “to estimate the magnitude of the error in
predicting the in vivo bioavailability results from in vitro dissolution data”.78 Two criteria,
internal and external criteria, are required for the validation process. (1) Internal
predictability is based on the initial data used to define the IVIVC model and should be
studied for all IVIVCs. The criteria of internal predictability are that “average absolute
percent prediction error (% PE) of 10% or less for Cmax and AUC establishes the
predictability of the IVIVC. In addition, the %PE for each formulation should not exceed
15%”. Percent prediction error (% PE) is calculated by Equation 1-1. (2) Evaluation of
% PE 

Observed value  Pr edicted value
 100
Observed value

(Eq. 1-1)

external predictability of the IVIVC should be performed as a final determination of
established IVIVC to be used as a surrogate for bioequivalence if the internal
predictability of the IVIVC is inconclusive.78 This evaluation is based on additional test
data set that was not used in developing the IVIVC model, and the important criterion is
that “% PE of 10% or less for Cmax and AUC establishes the external predictability of an
IVIVC”.
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CHAPTER 2. DEVELOPMENT OF A SUSTAINED RELEASE
BUPRENORPHINE FORMULATION FOR MAINTAINING PROLONGED
ANALGESIA IN RATS AND MICE
2.1.

Introduction

Rodents are the most universally used laboratory animals and are often subjected
to research involving painful procedures. In US, the National Association for Biomedical
Research (NABR) estimated that 23 million rats and mice were needed for research in
1998 and that rodents accounted for 95% of the animals used.80 The Home Office showed
that 3.6 million animals were used in scientific procedures in 2010 and 80% of them were
rats and mice in the UK.81 Animal welfare regulations require that anesthetic or analgesia
should be provided to the animals involved in painful procedures.
Numerous studies cite buprenorphine as a potent opioid analgesic for managing
pain in rodents as it exhibits excellent analgesic activity and minimal side effects.12,82-87 A
survey of current literature indicates that buprenorphine is one of the most widely used
analgesics in rodents for its excellent analgesic activity and long duration of action 68,88-90
and has been extensively used in both laboratory and companion animals for almost three
decades.90 Buprenorphine has a complex pharmacological profile. It is generally accepted
that buprenorphine is μ-opioid receptor partial agonist, κ-opioid receptor antagonist, and
δ-receptor agonist.87 It has a broad analgesic profile, relative wide safety margin91 and
offers the opportunity to treat different pain conditions for rodents.92 Elizabeth A. Tolley
et al demonstrated that buprenorphine has a analgesia duration of 6 to 8 hr in rats (0.5
mg/kg) and 3 to 5 hr in mice (2.0 mg/kg) after subcutaneous injection buprenorphine
solution using conventional hot-plate and tail-flick assays.93 But in order to maintain
effective analgesia levels, buprenorphine must be administered at least 2 or 3 times daily
for each animal. Frequent dosing requires more personnel effort and more handling to the
animals. However, no commercial sustained release analgesic for rodents was available
when we started the project in 2008. In 2011, Patricia L Foley68 published a
biodegradable polymer delivery system composited of buprenorphine hydrochloride, a
biocompatible organic solvent, and DL-lactide-ε-caprolactone copolymer with an average
molecular weight of approximately 5500 Da. It was claimed that this product could
provide a 48 to 72 hours period of analgesia for rats. But skin irritation is potentially a
problem for this product.68 The other disadvantage of this product is that the cost of
biodegradable polymer delivery system is much higher than the hydrophobic based
solution system.
Parenteral long-acting lipophilic solutions have been in clinical use for more than
three decades.94 Compared with other parenteral delivery system, the composition is
relatively simple and has the attributes94 of uncomplicated manufacture and feasible longterm stability. Some citric acid esters, such as acetyl triethyl citrate (ATEC), acetyl
tributyl citrate (ATBC), acetyl trihexyl citrate, and acetyl trioctyl citrate, are safe to use in
cosmetics.95 Both ATEC and ATBC were nonirritating to the skin in rabbits and human
clinical studies.95 These indicated the potential to apply citric acid esters as nonirritating
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and low cost vehicles in drug delivery. In order to reduce the stress of frequent handling
and injection as well as improve the welfare of research animals, this study developed a
long-acting sustained release hydrophobic formulation of buprenorphine which is capable
of maintaining analgesia in rats and mice for 3 to 5 days following a single subcutaneous
administration.
2.2.
2.2.1.

Materials and Methods

Materials

Buprenorphine base was obtained from Diosynth Inc. (Morrisville, NC). Triethyl
citrate (TEC), acetyl triethyl citrate (ATEC), tributyl citrate (TBC) and acetyltributyl
citrate (ATBC) were obtained from Vertellus Specialties Inc. (Greensboro, NC).
Polyethylene glycol 400 (PEG 400) was obtained from Dow Chemicals, Inc. (Danbury,
CT). Soybean oil and corn oil were obtained from Croda, Inc. (Columbus Circle Edison,
NJ). Ethyl benzoate and benzyl benzoate were purchased from Sigma Aldrich (Atlanta,
GA).
2.2.2.

Animals

Male Sprague Dawley rats (approximately 300 g) and mice (approximately 30 g)
were obtained from Charles River Laboratories (Wilmington, MA). The animals were
group-housed in polycarbonate caging with ad libitum access to food and water. The
experiments were conducted according to protocols approved by the Institutional Animal
Care and Use Committee (IACUC).
2.2.3.

Analytical methodology for in vitro and in vivo studies

2.2.3.1. Analytical methodology for in vitro studies
Two different HPLC methods were developed to quantitate buprenorphine in
samples obtained from in vitro studies. Method 1 was used for equilibrium solubility and
dissolution studies. Method 2 was used for stability studies. A silica-gel column was used
in Method 2 rather than C-18 column in Method 1 was because multiple injections of
buprenorphine samples containing highly lipophilic excipients resulted in contamination
of C-18 column and low sensitivity of the assay.
2.2.3.1.1. HPLC method 1 for equilibrium solubility and dissolution studies
The mobile phase used in method 1 was composed of a mixture of 51 mM
KH2PO4 buffer (pH 5.35) containing 0.0675% (v/v) of 2N NaOH and acetonitrile (45:55,
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v/v). A discovery C-18 column (2.1 x 100 mm) (Supelco, Bellefonte, PA) was used. The
oven temperature was 40°C and the flow rate was 0.3 mL/min. The total run time was 6
minutes. Buprenorphine was detected with a florescence detector at λExitation = 292 nm and
λEmission= 350 nm.
2.2.3.1.2. HPLC method 2 for stability studies
Waters Silica-gel column (4.6х150 mm) (Milford, MA) was used for this method.
The mobile flow rate was 1.0 mg/min. A mixture of 50 mM sodium acetate (pH was
adjusted to 3.75 with acetic acid) and acetonitrile (20:80, v/v) was used as the mobile
phase. Total run time was 7 minutes. Buprenorphine was detected with florescence
detector at λExitation = 292 nm and λEmission= 350 nm.
2.2.3.1.3. Preparation of standard solutions
The primary standard stock solution (1.68 mg/mL) for the validation study of
Method 1 was prepared by accurately weighing 16.8 mg of buprenorphine, dissolving it
with acetonitrile and diluting the resulting solution to 10 mL with acetonitrile. The
secondary standard working solutions (0.038, 0.076, 0.38, 7.6 and 38 μg/mL) were
prepared by serially diluting the primary standard stock solution with 50% ACN. To test
intra-day accuracy, a set of standard samples were injected 3 times on the same day. To
test inter-day accuracy, three sets of standard samples were freshly prepared individually
every day and then injected once every day.
The primary standard stock solution (1.17 mg/mL) for the validation study of
Method 2 was prepared by accurately weighing 11.7 mg of buprenorphine, dissolving it
with acetonitrile and diluting to 10 mL with additional acetonitrile. The secondary
standard working solutions (0.03, 0.12, 0.29, 1.17 and 5.85 μg/mL) were prepared by
serially diluting the primary standard stock solution with 50% ACN. To test intra-day
accuracy, a set of standard samples were injected 5 times on the same day. To test interday accuracy, three sets of standard samples were freshly prepared individually every day
and then injected once every day.
2.2.3.2. Analytical methodology for in vivo studies
Validated LC/MS/MS methods were developed for quantifying the drug
concentrations in plasma samples obtained from in vivo studies.
2.2.3.2.1. Equipment
The HPLC system consisted of two Shimadzu LC-10ADvp pumps (Shimadzu
Scientific Instruments Inc., Columbia, MD), a Shimadzu SIL-HTc autosampler, and a
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HILIC silica column (5 m, 150 × 4.6 mm) with a guard column (10 × 2.1 mm) (Waters
Inc., Milford, MA). Harvard syringe pump (Harvard Apparatus, South Natick, MA). API
4000 tandem triple quadrupole mass spectrometer (Applied Biosystems, Foster City, CA)
and Source SF 5000 LC/MS Gas Generator (Parker Hannifin, Haverhill, MA) were also
used. Analyst® software (Applied Biosystems, Version 1.4.1, Foster City, CA) was used
for data acquisition and processing.
2.2.3.2.2. HPLC conditions
A gradient method was used to supply eluent to the mass spectrometer. The
mobile phase consisted of solutions A and B. Solution A consisted of ACN : water :
formic acid (4.95:95:0.05, v/v) containing 2 mM ammonium formate. Solution B
consisted of ACN : water : formic acid (95:4.95:0.05, v/v) containing 2 mM ammonium
formate. The time program of the gradient method was such that it started with 90% of
Solution B and 10% of Solution A. The concentration of Solution B was then decreased
linearly from 90% to 40% within 3.5 minutes and then immediately increased to 90% and
maintained at 90% for 2 minutes. The concentration of Solution B was then decreased
linearly from 90% to 40% within 0.5 minute and then linearly increased to 90% within
0.5 minute and maintained at 90% for 4 minutes. The total run time was 10 minutes. The
column was operated at room temperature and the flow-rate of the mobile phase was 0.5
mL/min.
2.2.3.2.3. Switch valve
The eluent from the HPLC system was only introduced directly into the mass
spectrometer between running time of 4.6 min and 5.6 min. The eluent from the HPLC
system within the first 4.6 minutes and after 5.6 minutes was introduced directly into the
waste collector.
2.2.3.2.4. MS conditions
The MS was set in the positive ion mode. The ion-spray voltage was 5.0 kV and
desolvation temperature was 600ºC. Ion source gas one, ion source gas two, curtain gas
and collision gas flows were set at 55, 60, 14, and 6 of the instrument units, respectively.
The mass analyzer was set at multiple-reaction-monitoring (MRM) mode with a dwell
time of 300 ms for each ion pair. Ion transition of 468.3 to 468.3 was selected for
buprenorphine detection and 472.3 to 472.3 for buprenorphine-D4 detection. The
compound dependent parameters for buprenorphine and buprenorphine-D4 were as
follows: declustering potential (DP) of 47, entrance potential (EP) of 10, collision energy
(CE) of 50, and collision cell exit potential (CXP) of 13. Resolution of the mass analyzer
was set at unit resolution. Optimization of the mass spectrometric conditions were
carried out by infusing 50 ng/mL of analyte solution dissolved in a mixture of acetonitrile
and water (50/50, v/v) at 10 L/min using a syringe pump.

22

2.2.3.2.5. Process of plasma samples
The internal standard solution (50 ng/mL) of buprenorphine-D4 was prepared by
diluting buprenorphine-D4 standard solution (100 g/mL) with 0.1% formic acid
solution. Twenty-five microliters of rat plasma was spiked with 25 µL of BuprenorphineD4 internal standard solution and 25 L of 50% ACN. The resulting mixture was mixed
well by vortexing for 10 seconds and centrifuged at 14K rpm for 1 minute, and then
deproteinated by adding 25 L of 15% trichloroacetic acid solution. The mixture was
then vortexed for one minute and kept in -20ºC for 30 minutes. The samples were then
centrifuged for 10 minutes at 14k rpm using an Eppendorf 5415C centrifuge (Brinkman
Instruments Incorporated, Westbury, NY). The supernatant was transferred to HPLC
sample vials and the drug content of the samples was determined by the above mentioned
validated LC/MS/MS assay. The ratio of peak area of buprenorphine to that of peak area
of buprenorphine-D4 was used to determine the buprenorphine plasma concentration.
2.2.3.2.6. Preparation of calibration standard samples and quality control samples
The primary standard stock solution (500 g/mL) for buprenorphine calibration
standard samples was prepared by accurately weighing approximately 25 mg of
buprenorphine and dissolving it in 10 mL volumetric flask with ACN. The secondary
standard working stock solutions with the following concentrations - 0.4, 2, 10, 50, 100,
150, 200, and 250 ng/mL were prepared by serially diluting the primary standard stock
solution with 50% ACN. The calibration standard samples were prepared as follows:
twenty-five microliters of rat plasma was spiked with 25 µL of Buprenorphine-D4
internal standard solution and 25 L of secondary standard working stock solutions. The
resulting mixture was mixed well by vortexing for 10 seconds and centrifuged at 14K
rpm for one minute, and then deproteinated by adding 25 L of 15% trichloroacetic acid
solution. The mixture was then vortexed for one minute and kept at
-20ºC for 30 minutes. The samples were then centrifuged for 10 minutes at 14k rpm
using a centrifuge. The supernatant was transferred to HPLC sample vials and the drug
content of the samples was determined by a validated LC/MS/MS assay.
Four standard samples (2, 50, 100, 200 ng/mL) were injected three times in the
same day to test the intra-day accuracy assay. Two more sets of the standard samples (2,
50, 100, 200 ng/mL) were freshly prepared in different day and analyzed to test the interday variation. The primary quality control (QC) stock solution (500 μg/mL) was
independently prepared by weighing approximately 25 mg of buprenorphine powder and
dissolving it with ACN. The QC working solutions (2, 50, 100, and 200 ng/mL) were
prepared by serially diluting the primary QC stock solution with 50% ACN solution.
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2.2.4.

In vitro studies

2.2.4.1. Determination of equilibrium solubility of buprenorphine
Buprenorphine base powder (approximately 300 mg) was suspended in 1.0 mL of
solvents (TEC, ATEC, TBC, ATBC, Ethyl benzoate, benzyl benzoate, PEG 400, soybean
oil and corn oil) in 2.0 mL Eppendorf centrifuge tubes. After vortexing, the resulting
suspensions were then shaken at 100 rpm in a shaking incubator maintained at 25ºC and
37ºC. After 1, 2 and 5 days, the suspensions were vortexed again and then centrifuged at
12K rpm for 5 minutes. Approximately 100 µL of the clear supernatant was carefully
removed and the buprenorphine samples were diluted with acetonitrile. One milliliter of
this solution was further diluted with acetonitrile-water mixture (50:50, v/v) and analyzed
using a validated HPLC method.
2.2.4.2. Determination of stability of buprenorphine in various solvents
Approximately 200 µL of saturated or nearly saturated buprenorphine solutions in
different solvents (TEC, ATEC, TBC, ATBC, Ethyl benzoate, benzyl benzoate, PEG 400,
soybean oil and corn oil) were diluted to 10 mL by adding the respective solvents. After
filtration, the resulting solutions were stored at 25ºC and 40ºC. At 0, 7, 14, 21 and 28 day,
100 µL of the solutions were removed from the containers and diluted to 10 mL in
volumetric flasks with acetonitrile. The resulting diluted solution was then analyzed for
drug content using a validated HPLC method.
2.2.4.3. In vitro drug release study
Six solvents were selected for in vitro formulation screening test based on the
results of aforementioned studies. An appropriate amount of buprenorphine base powder
was accurately weighed and added to an appropriate amount of solvent in 20 mL glass
scintillation vials. The subsequent suspension was sonicated in a water bath maintained
less than 25ºC until all drug powder was dissolved. The drug content was verified by
HPLC method. The formulation composition was listed in Table 2-1 and the
buprenorphine concentration is 1.5% (w/w).
Approximately 210 mg of buprenorphine solution was weighed and carefully
transferred into the cavity of a Teflon cylinder (internal diameter of the cavity was 15.0
mm, internal depth was 4.1 mm, height of the cylinder was 12.3 mm, and the outside
diameter of the cylinder was 20 mm). The solution-loaded Teflon was then covered with
a 40-mesh USP basket and centered at the bottom of 1L dissolution vessel.
Approximately 900 mL of 10% isopropyl alcohol (IPA)-40% water-49.95% phosphate
buffer saline solution (PBS) (v/v/v) dissolution medium (pH 7.4) containing 0.05% SDS
was carefully transferred into each vessel at the rate of 7 mL/sec using modified Hanson
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Table 2-1.
studies.

Buprenorphine sustained release formulations for in vitro dissolution

Formulation

Solvent

Concentration of Buprenorphine in Solvent
(w/w)

1
2
3
4
5
6

TEC
ATEC
TBC
ATBC
Benzyl Benzoate
Ethyl Benzoate

1.5%
1.5%
1.5%
1.5%
1.5%
1.5%
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Media Mate (Hanson Research Corp.). The ion strength calculated by Debye–Hückel
equation was adjusted by sodium chloride and kept at 0.13. The new designed apparatus
was used and the paddle speed was set at 100 rpm. The details of the apparatus will be
discussed in Section 3.3.6.1. The vessels were covered with a lid and tightened with
laboratory para-film in order to avoid evaporation of the medium.
The in vitro drug release studies were conducted in triplicate. At 0, 30 min, and 1,
2, 4, 6, 9, 12, 24, 36, 48, 60, 72, 84, 96 and 120 hours. Approximately 1 mL dissolution
medium was carefully withdrawn by Hanson Autosampler (Hanson Research Corp.) and
replaced with 1 mL pre-warmed fresh dissolution medium. The dissolution samples were
filtered through 0.45 µm PVDF membranes and analyzed for drug content using the
validated HPLC Method.
2.2.5.

In vivo studies

2.2.5.1. Measurement of analgesia in rats and mice using the tail flick method
The tail flick method is classic method to evaluate the pain of analgesic. The tailflick test apparatus (Model 33, IITC Life Science, Woodland Hills, CA) was used to
measure analgesia in animals following the administration of the buprenorphine
solutions. In the tail flick test, the animal tail was exposed to a hot-light beam. When the
pain threshold was reached, the animal flicked the tail away from the heat beam. The
time is recorded and the analgesic effect at each time point was reported as the
Percentage of Maximum Possible Effect (% MPE). This method compares the latency at
each time point with the animal’s own average baseline latency. %MPE was calculated
using Equation 2-1.
%MPE 

Latency  Baseline Latency
 100%
Cutoff Time  Baseline Latency

(Eq. 2-1)

where latency is the response time for the animal to flick the tail away from the hot light
beam; the cutoff time was set at 10 seconds to prevent any possible tissue damage; and
the baseline latency for each animal was obtained 24 hours prior to the administration of
the formulations and reported as the average value of three measurements. The intensity
of light beam was set at the conditions under which the baseline latency of a normal
untreated rat was approximately 3 to 4 seconds.
2.2.5.2. PK and PD studies of buprenorphine in rats after an intravenous injection of
buprenorphine solution
Six male Sprague Dawley rats with implanted vascular access ports (VAP) were
used in this study. Before blood samples were withdrawn, the pharmacodynamic activity
was evaluated via aforementioned tail flick method. Rats were then anesthetized lightly
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with isoflurane, and 0.05 mg/kg of aqueous solution of buprenorphine hydrochloride was
injected intravenously via saphenous vein over 10 sec. Blood samples (0.2 mL) were
withdrawn through the VAP at 0, 5, 15, and 30 min, and 1, 2, 3, 6, 12 and 24 hr after
administration, and collected in heparinized vial. Plasma was separated from whole blood
by centrifuging the blood samples at 14k rpm for 7 min and stored at -20ºC until analyzed
for drug content. Plasma samples were processed and then analyzed using the validated
LC/MS/MS method.
2.2.5.3. PK and PD studies of buprenorphine in rats after a subcutaneous injection of
buprenorphine sustained release formulations
An appropriate amount of buprenorphine base powder was accurately weighed
and added to an appropriate amount of TBC in 20 mL glass scintillation vial (Tables 2-2
and 2-3). The subsequent suspension was sonicated periodically in a water-bath
maintained less than 25°C until all drug powder was dissolved. The final solution was
obtained by filtering the above solution through a 0.22 μm syringe filter into 20 mL
presterilized glass vial in a sterile hood and the drug concentration was verified by HPLC
method.
Table 2-2 lists all the investigated buprenorphine formulations in rat studies. The
tested solvents were selected based on the results of the solubility and stability studies.
During the animal experiment, buprenorphine solutions (~ 0.2 mL) were administered
subcutaneously into rats. The syringes were weighed before and after subcutaneous
administration of the solutions, and the exact weight of the buprenorphine solution
administered to each rat was noted.
Before blood samples were withdrawn, the pharmacodynamic activity was
evaluated via aforementioned tail flick method. Blood samples (~ 0.2 mL) were then
withdrawn from the saphenous vein at predetermined time points and kept in heparinized
Microvette tubings (Microvette CB 300 LH, Sarstedt, Nümbrecht, Germany). The
collected blood samples were immediately centrifuged at 14K rpm for 7 min and plasma
samples were stored at -20°C until further analysis. The plasma samples were processed
and analyzed for drug content using the validated LC/MS/MS method. The plasma
concentration at each time point was reported as average ± SD (standard deviation). At
120 hours (day 5) after subcutaneous administration of the buprenorphine solutions, the
rats were anesthetized by overdosing with isoflurane, followed by pneumothorax
euthanasia. The injection sites on the carcasses were carefully dissected and the injection
site of the subcutaneous tissue was exposed, inspected for any residues or for any gross
inflammation, and photographed.
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Table 2-2.

Buprenorphine sustained release formulations tested in rats.

Formulation

Solvent

R1
R2
R3

TBC
TBC
TBC

Table 2-3.

Concentration of Buprenorphine
(mg/g)
3.08
5
8.5

Dose
(mg/kg)
1.5
2.25
5

Buprenorphine sustained release formulations tested in mice.

Formulation

Solvent

M1
M2
M3

TBC
TBC
TBC

Concentration of Buprenorphine
(mg/g)
3.9
0.87
0.44
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Dose
(mg/kg)
8.9
2.2
1.1

2.2.5.4. PK and PD studies of buprenorphine in mice after subcutaneous injection of
buprenorphine sustained release formulations
Based on the results from rat studies, three buprenorphine formulations (Table
2-3) were selected, prepared and tested in mice. Approximately 50 µL of buprenorphine
solutions were administered subcutaneously in mice using 25-gauge needles. The
syringes were weighed before and after subcutaneous administration of the solutions, and
the exact weight of the buprenorphine solution administered to each mouse was noted.
At predetermined time points after the administration, the analgesic activity of
each formulation was evaluated via tail flick method in five mice and the average
analgesic effect at each time point was reported as the Percentage of Maximum Possible
Effect (%MPE). Immediately after the PD study, blood samples (0.6~1 mL) were
collected by cardiac puncture method and placed in 1.5 mL heparinized centrifuge tubes.
Then the mice were sacrificed by cervical dislocation under isoflurane anesthesia. The
injection sites of the subcutaneous tissue were carefully dissected, exposed, inspected for
any gross inflammation, and photographed for any residues. The collected blood samples
were immediately centrifuged at 14K rpm for 15 min and plasma samples were stored at 20ºC until further analysis for drug content using the validated LC/MS/MS method. The
average plasma concentration at each time point was reported.
2.2.5.5. Toxicity evaluation of citric acid esters in rats
Approximately 200 µL of each of the sterilized citric acid esters (TEC, ATEC,
TBC and ATBC) or normal saline were subcutaneously administered to four male SD
rats. The animals were monitored for signs of toxicity and were weighed daily. Their
eating and drinking habits were also closely monitored.
2.3.
2.3.1.

Results and Discussion

Validation of analytical methodology

2.3.1.1. Validation of HPLC assay for in vitro studies
The standard curves of Method 1 and Method 2 are listed.



The standard curve of method 1 was: Peak area = 405278 * C (μg/mL)
+ 29.27 (R = 0.9997)
The standard curve of method 2 was: Peak area = 114685.7 * C (μg/mL)
- 289.9 (R = 0.9998)
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Tables 2-4 and 2-5 show the intra- and inter-day variations of Methods 1 and 2
respectively. The results show that both methods were reproducible and accurate. The
samples obtained from solubility studies and dissolution studies were analyzed using
HPLC Method 1. A narrow and sharp buprenorphine peak (retention time was 4.30 min)
was obtained with the C-18 column and the number of theoretical plates (N) for
buprenorphine was around 2,200. The Lower Limit of Detection (LLOD) of the assay for
buprenorphine was 20 ng/mL. The LLOQ of the assay was 42 ng/mL. The samples from
stability studies were analyzed using HPLC Method 2. A narrow and sharp
buprenorphine peak (retention time was 3.8 min) was obtained with the silica-gel column
and the column efficiency for buprenorphine (N) was approximately 6,000. The Lower
Limit of Quantification (LLOD) of the assay was 12 ng/mL. The LLOQ of the assay was
29 ng/mL. There was no interference between the buprenorphine and solvents peaks.
2.3.1.2. Validation of LC-MS/MS assay for in vivo studies
No significant interference was observed from the endogenous compounds at the
retention times of the analytes using the optimized LC-MS/MS conditions. Moreover, the
chromatographic retention times of both buprenorphine and buprenorphine-D4 were 5.1
min and showed symmetrical peak shapes. The standard curve of buprenorphine was
linear (Equation 2-2, R = 0.9998) in the entire range of the standard solutions (0.4
ng/mL to 250 ng/mL):
AUC buprenorphine
AUC buprenorphine- D4

 0.01135  0.02024  C buprenorphine

(Eq. 2-2)

where AUCbuprenorphine and AUCbuprenorphine-D4 are peak area of buprenorphine and
buprenorphine-D4, respectively, and Cbuprenorphine is the concentration of buprenorphine.
The LLOD of the assay for buprenorphine was 0.01 ng/mL and the LLOQ of the
assay for buprenorphine was 0.4 ng/mL. The intra-day and inter-day variations of the
assay developed for the in vivo studies are shown in Table 2-6. The results showed that
the developed assay was reproducible and accurate.
2.3.2.

In vitro studies

In order to test the effect of the hydrophobic vehicle with the varying
hydrophilicity/lipophilicity on the drug release, nine vehicles were tested in solubility and
stability studies. PEG 400, TEC, ethyl benzoate, ATEC, benzyl benzoate, TBC, ATBC,
soybean oil and corn oil have different hydrophilicity and lipophilicity, and have been
applied in pharmaceutical products. PEG 400 96 is member of polyethylene glycol family.
It is a clear, colorless or slightly yellow-colored, viscous liquid. It is widely used in a
variety of pharmaceutical products, such as parenteral, topical, ophthalmic, oral and
rectal preparations. Intraperitoneal LD50 of PEG 400 is 10.0 g/kg for mouse and 9.7 g/kg
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Table 2-4.

Intra-day (n = 3) and inter-day (n = 3) variation of the assay 1.

Buprenorphine Concentration
(μg /mL)
0.038
0.076
0.38
7.6
38

Table 2-5.

Inter-day RSD
(%)
3.4
9.3
6.4
6.2
4.6

Intra-day (n = 5) and inter-day (n = 3) variation of the assay 2.

Buprenorphine Concentration
(μg/mL)
0.03
0.12
0.29
1.17
5.85

Table 2-6.

Intra-day RSD
(%)
5.82
3.52
0.41
0.51
0.53

Intra-day RSD
(%)
15.0
4.7
3.1
1.4
5.0

Inter-day RSD
(%)
NA
4.8
4.5
2.1
1.0

Intra-day and Inter-day variation of the LC-MS/MS assay (n=3).

Buprenorphine Concentration
(ng/mL)
0.3654
3.654
49.54
104.4
195.75

Intra-day RSD
(%)
12.8
1.8
0.5
0.2
0.4
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Inter-day RSD
(%)
14.0
3.2
4.0
3.0
2.5

for rat. Intravenous LD50 is 9.7 g/kg for rat. The cLogP value is - 4.8 and it is
hydrophilic solvent. Triethyl citrate (TEC) 96 is a clear, viscous, odorless, and practically
colorless, hygroscopic liquid with cLogP value of 1.45. It has been used as plasticizer in
film coating. It has favorable safety profile and good stability. TEC has been accepted as
a direct food additive by the U. S. Food and Drug Administration. LD50 is 5.9 g/kg in
rats after subcutaneous administration and 1.75 g/kg in mice after intraperitoneal
administration. Ethyl benzoate is a colorless liquid with cLogP values of 2.73. It is a
component of some artificial fruit flavors. Oral LD50 for rat is 2.1 g/kg. Acetyl triethyl
citrate (ATEC) 96 is a clear, odorless and colorless oily liquid with cLogP value of 3.73.
It is generally regarded as a nontoxic and nonirritating material. Oral LD50 in rats is 7.0
g/kg. Intraperitoneal LDso in mouse is 1.15 g/kg. FDA has approved its pharmaceutical
use as a plasticizing agent in coating. Benzyl benzoate96 is a clear, colorless, oily liquid
with a slightly aromatic odor with cLogP value of 3.97. It is used as a solubilizing agent,
plasticizer and nonaqueous solvent in intramuscular injections at concentrations of 0.01–
46.0% (v/v) in pharmaceutical products. It is also used as a solvent and fixative for
flavors and perfumes in cosmetics and food products. Besides, it is as a topical
therapeutic agent in the treatment of scabies and therapeutically as a parasiticide in
veterinary medicine. Oral LD50 is 1.4 g/kg for mouse and 0.5 g/kg for rat. Tributyl
citrate (TBC) 96 is a clear, odorless, practically colorless, oily liquid with cLogP value of
4.68. It is considered as chemically inert and safe material. FDA has approved its
pharmaceutical use as a plasticizing agent in coatings. Oral LD50 in rats is more than 30
mL/kg. Intraperitoneal LD50 in mouse is 2.9 g/kg. Acetyl tributyl citrate (ATBC) 96 is a
clear, odorless, practically colorless, oily liquid with cLogP value of 6.92. It is used in
oral, topical pharmaceutical formulations and films intended for direct food contact. It is
generally regarded as a relatively nontoxic and nonirritating material. Intraperitoneal
LD50 for mouse is more than 4 g/kg and oral LD50 for rat is more than 31.5 g/kg. The
skin irritation testing in rabbits showed that neither ATEC nor ATBC induced skin
irritation.95 Soybean oil96 is a clear, pale-yellow colored, odorless or almost odorless
liquid with a bland taste. It is used in cosmetics, pharmaceutical products and as bath
additive to treat dry skin. In pharmaceutical products, it is used in parenteral nutrition
vehicles for the oral and intravenous administration of drugs, and has been used in drug
delivery systems such as liposomes, microspheres, emulsions, self-emulsifying systems,
emulsions, nanoemulsions, and nanocapsules, solid-in-oil suspensions, and multiple
emulsions. The intravenous LD50 is 22.1 g/kg for mouse and 16.5 g/kg for rat.
2.3.2.1. Equilibrium solubility studies
Table 2-7 lists the solubility of buprenorphine base in different solvents. It is
apparent from the table that the drug has the highest solubility in ethyl benzoate, and
lowest in corn oil and soybean oil at both 25 and 37C. The estimated minimum
solubility was approximately 10 mg/mL calculated from the equation R0 = Css·CL, where
the R0 is infusion rate, Css is plasma concentration at steady state, and CL is clearance.
The clearance was from following PK study after intravenous injection of buprenorphine
saline solution. The Css was obtained from the study after subcutaneous of buprenorphine
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Table 2-7.

Solubility of buprenorphine in different vehicles.

Solvent
(mg/mL)
TBC
ATBC
TEC
ATEC
Ethyl benzoate
Benzyl benzoate
PEG 400
Soybean oil
Corn oil

Day 1
27.2 ± 1.7
18.9 ± 0.8
19.2 ± 0.3
14.7 ± 0.2
95.7 ± 0.2
47.5 ± 1.0
20.2 ± 0.6
10.1 ± 0.2
10.1 ± 0.7

@25ºC
Day 2
28.5 ± 0.2
20.7 ± 1.6
18.6 ± 0.3
14.9 ± 0.1
95.9 ± 1.4
47.0 ± 0.3
21.6 ± 0.2
11.0 ± 0.1
11.3 ± 0.4

Day 5
28.0 ± 0.3
20.0 ± 1.0
19.1 ± 0.9
14.1 ± 0.6
95.8 ± 1.0
47.5 ± 1.3
20.6 ± 0.8
10.4 ± 0.1
10.5 ± 0.3

Data are presented as mean ± SEM (mg/mL).
n = 3.
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Day 1
30.2 ± 0.2
20.1 ± 0.8
20.7 ± 0.1
16.2 ± 0.3
102.7 ± 1.0
48.3 ± 0.5
23.4 ± 0.7
11.0 ± 0.3
11.0 ± 0.2

@ 37ºC
Day 2
30.3 ± 0.6
22.5 ± 0.5
22.6 ± 0.8
17.3 ± 0.4
113.8 ± 1.3
50.1 ± 0.3
24.9 ± 0.4
10.6 ± 0.9
11.2 ± 02

Day 5
29.9 ± 0.7
23.0 ± 1.1
21.3 ± 1.1
17.3 ± 0.7
112.2 ± 1.7
49.4 ± 1.4
24.6 ± 0.4
11.6 ± 0.6
10.8 ± 0.1

saline solution in rats. The results of calculation showed that the solubility of all the
tested vehicles was more than 10 mg/mL and met the requirement of minimum solubility.
2.3.2.2. Stability studies
Figure 2-1 and Table 2-8 show the short-term stability of buprenorphine base in
different solvents. It is apparent from the table that buprenorphine base was stable in all
the solvents at 25ºC for at least 30 days, but was not stable in PEG 400, soybean oil, corn
oil and ATEC at 40ºC for one month. Therefore, TEC, TBC, ATBC, ethyl benzoate,
benzyl benzoate were selected for in vitro dissolution study.
2.3.2.3. Dissolution studies
Buprenorphine in the oil vehicles of TEC, ATEC, TBC, ATBC, ethyl benzoate,
benzyl benzoate were selected for in vitro dissolution study. Buprenorphine in ATEC did
not show the promising stability for one month, but it is one of the citric acid esters with
moderate hydrophobicity and has the potential be used with other vehicle(s) in the
combination formulation. Therefore, the in vitro release profile of buprenorphine in
ATEC was also tested considering it was stable for 1 week at 40°C. Figure 2-2 shows the
effect of different vehicles on drug release. The release rate did not follow the order of
cLogP values, but it was evident from the figure that fastest drug release was observed
from formulation prepared with most hydrophilic vehicle, TEC, and 57.2% drug release
was detected at 120 hr. It was apparent from the figure that slowest drug release could be
achieved from the formulations prepared with lipophilic vehicles, benzyl benzoate and
TBC. Considering the LD50 of benzyl benzoate in rats (0.5 g/kg, oral) and mice (1.4
g/kg, oral), TBC showed the larger safety margin of LD50 in rats (>30mL/kg, oral) and
mice (2.9 g/kg, IP) and was selected as the vehicles for in vivo study.
2.3.3.

In vivo studies

2.3.3.1. PK and PD studies in rats after intravenous injection of buprenorphine saline
solution
Figure 2-3a shows the analgesia measured by the tail flick test in rats after an i.v.
administration of buprenorphine hydrochloride solution at the dose of 0.05 mg/kg. At 5
minutes after the i.v. injection, 100% MPE was obtained. Then the analgesia decreased
to 50% MPE within 9 hours, and no analgesia was observed after 24 hours after drug
administration. The plasma concentration of buprenorphine versus time profile after i.v.
injection in rats at a dose of 0.05 mg/kg is depicted in Figure 2-3b. Buprenorphine
plasma concentrations of 14.5 ng/mL were achieved within 5 minutes after the i.v.
injection. The concentration then rapidly decreased within the first 15 minutes, and then
declined more slowly thereafter. The concentration of buprenorphine in plasma was less
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Table 2-8.

Stability of buprenorphine base in different solvents.

Solvent
PEG 400

TEC

ATEC

TBC

ATBC

Soybean oil

Corn oil

Time
(Week)

% Drug Remaining
25°C
40°C

0
1
2
3
4
0
1
2
3
4
0
1
2
3
4
0
1
2
3
4
0
1
2
3
4
0
1
2
3
4
0
1
2
3
4

100.0 ± 2.7
100.6 ± 1.1
100.0 ± 3.3
99.1 ± 5.6
98.8 ± 1.0
100.0 ± 1.0
104.5 ± 1.2
101.7 ± 2.0
98.1 ± 0.3
97.7 ± 0.7
100.0 ± 0.1
100.9 ± 1.6
98.2 ± 1.0
96.8 ± 1.5
94.9 ± 0.5
100.0 ± 3.8
108.6 ± 0.5
108.1 ± 2.3
104.1 ± 3.4
104.9 ± 1.1
100.0 ± 2.9
102.5 ± 0.4
103.9 ± 1.1
101.0 ± 1.1
101.3 ± 0.3
100.0 ± 1.0
96.1 ± 2.2
98.7 ± 2.0
98.8 ± 0.6
94.8 ± 0.7
100.0 ± 2.1
95.5 ± 4.6
97.2 ± 1.8
96.8 ± 2.6
96.4 ± 1.0
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100.0 ± 2.7
95.8 ± 2.3
90.6 ± 2.5
79.0 ± 2.6
73.8 ± 2.2
100.0 ± 1.0
99.4 ± 1.6
101.8 ± 1.2
95.8 ± 1.0
97.4 ± 1.4
100.0 ± 0.1
99.5 ± 5.4
96.4 ± 0.4
91.6 ± 2.8
88.8 ± 3.8
100.0 ± 3.8
102.8 ± 1.9
106.5 ± 4.9
103.3 ± 5.1
102.8 ± 6.1
100.0 ± 2.9
103.7 ± 1.0
107.2 ± 3.5
96.9 ± 0.4
101.3 ± 1.4
100.0 ± 1.0
93.7 ± 9.8
79.4 ± 1.7
53.1 ± 2.9
34.8 ± 8.6
100.0 ± 2.1
97.5 ± 6.9
96.7 ± 1.8
75.9 ± 4.4
53.8 ± 4.5

Table 2-8.

(Continued).
Solvent

Ethyl Benzoate

Benzyl Benzoate

Time
(Week)
0
1
2
3
4
0
1
2
3
4

% Drug Remaining
25°C
40°C
100.0 ± 1.3
99.9 ± 0.7
101.3 ± 1.2
101.1 ± 6.6
99.6 ± 0.8
100.0 ± 0.9
99.6 ± 1.5
96.3 ± 0.6
103.8 ± 1.5
100.1 ± 1.7

Data are presented as mean ± SD.
n = 3.
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100.0 ± 1.3
98.3 ± 1.8
100.8 ± 4.3
102.5 ± 1.4
100.2 ± 1.5
100.0 ± 0.9
99.8 ± 1.9
99.7 ± 2.4
99.8 ± 2.9
100.4 ± 1.7
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% Released

50
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40
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30
20
10
0
0

24

48

Time (hr)

72
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Figure 2-2. In vitro release profile of buprenorphine from oily formulations
prepared with various hydrophobic vehicles.
Each data point represents an average of three measurements.
Standard deviation of three measurements is presented as error bars.
Buprenorphine concentrations in the different oily solvents were 1.5%.
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Figure 2-3. (a) Analgesic effect and (b) plasma concentration of buprenorphine in
rats after a single intravenous injection of buprenorphine hydrochloride solution at
the dose of 0.05 mg/kg.
Each data point represents an average of six measurements.
Standard deviation of six measurements is presented as error bars.
Intensity of the tail flick tester during the experiment is 60%.
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than the LLOQ of the assay after 6 hr after the i.v. injection. The PK parameters was
calculated and listed in Table 2-9.
2.3.3.2. PK and PD studies in rats after subcutaneous injection of buprenorphine
sustained release formulations
Figure 2-4b shows the effect of different doses (1.5 mg/kg, 2.25 mg/kg and 5
mg/kg) on buprenorphine plasma concentrations in rats after a single subcutaneous
injection of formulations prepared with TBC. It is apparent from the figure that drug
release occurred in a controlled manner from the buprenorphine solution and
buprenorphine plasma concentrations increased proportionately as the dose of the drug
was increased from 1.5 to 2.25 to 5 mg/kg. At the dose of 5 mg/kg, buprenorphine
solution was able to achieve average Cmax of 22 ng/mL at 12 hours and maintain the
average plasma concentrations above 7.8 ng/mL for 5 days. The average Cmax was 12
ng/mL at 9 hours in rats that received buprenorphine solution at the dose of 2.25 mg/kg
dose. The solution was able to maintain the average plasma concentration above 3.4
ng/mL for 120 hours (5 days). Meanwhile, the average Cmax was 3.4 ng/mL at 6 hours in
the rats administered with buprenorphine solution at the dose of 1.5 mg/kg dose. The
solution was able to maintain the average plasma concentration above 2.3 ng/mL for 120
hours (5 days).
The pharmacology profile of buprenorphine has the character of bell-shaped12,13,87
dose-response curve for the antinociceptive action. The exact reason is not clarified and
the possible reasons could be 2-receptor model and noncompetitive autoinhibition.16,87,97
The peak of the dose-response curve was found to be occurred at a dose of 3 mg/kg in the
rat tail dip test using water at 45°C or 55°C as the noxious stimulus.7 Figure 2-4a
indicates that the best analgesia is achieved at the dose of 1.5 mg/kg. More than 55.1%
MPE analgesia was maintained for 72 hours after administration. Then the analgesia
declined to 20.1% MPE at 121 hours. The results shows that maintenance of higher
plasma concentrations may not be necessary for achieving and maintaining better
analgesia for a longer prolonged period of time.
2.3.3.3. In vivo evaluation of buprenorphine sustained release formulations in mice
Figure 2-5 shows the effect of varying buprenorphine doses (1.1 mg/kg, 2.2
mg/kg, 8.9 mg/kg) on analgesia and buprenorphine plasma concentrations in mice after a
single subcutaneous injection of formulations prepared with TBC (Table 2-3). It is
apparent from the Figure 2-5a that there is no significant difference in the maintenance
of analgesia for up to 48 hours after injecting either 8.9 or 2.2 mg/kg dose, and greater
than 52.7% analgesia was maintained for 48 hours after administering either doses of
buprenorphine. Then the analgesia declined to 49% MPE at 72 hours (3 days) and 31%
MPE at 120 hours (5 days) after injecting 8.9 mg/kg dose. After injecting 2.2 mg/kg dose,
the analgesia declined to 30% MPE at 72 hours (3 days) and 17% MPE at 120 hours (5
days). Meanwhile, approximately 98% MPE - initial high analgesia was achieved at 3
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Table 2-9.
PK parameters of buprenorphine in rats after a single intravenous
injection at the dose of 0.05 mg/kg.
t0.5
(hr)
0.59 ± 0.11

Vss
(L/kg)
3.60 ± 0.63

Data are presented as mean ± SD.
n = 6.
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Cl
(L/hr/kg)
4.89 ± 0.67

1.5 mg/kg, n=5, intensity 45%
2.25 mg/kg, n=6, intensity 50%

100
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n=4, intensity 50%
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Figure 2-4. Effect of varying buprenorphine dose on (a) analgesia and (b)
buprenorphine plasma concentration in rats after a single subcutaneous injection of
the formulations prepared with TBC.
Each data point represents an average of n measurements.
Standard deviation of the measurements is presented as error bars.
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Figure 2-5. Effect of doses on (a) analgesia (n=5) and (b) buprenorphine plasma
concentrations in mice after subcutaneous injection of formulations.
Each data point represents an average of the measurements.
Standard deviation of the measurements is presented as error bars.
Intensity of the tail flick tester during the experiment is 30%.
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hours after a single subcutaneous injection of 1.1 mg/kg dose. Then the analgesia
declined to 57.5% MPE at 24 hours (1 day) and 13% MPE at 120 hours (5 days).
Figure 2-5b shows that buprenorphine plasma concentrations increased
proportionately as the dose of the drug increased from 1.1 to 2.2 to 8.9 mg/kg. For the 1.1
mg/kg dose, the average Cmax was 6.2 ng/mL at 3 hours, and the average plasma
concentration was maintained above 1.4 ng/mL for 24 hours and above 0.3 ng/mL for 3
days. For the 2.2 mg/kg dose, the average Cmax was 10.2 ng/mL at 3 hours, and the
average plasma concentrations was maintained above 0.8 ng/mL for 3 days and above 0.1
ng/mL for 5 days. For the 8.9 mg/kg dose, the average Cmax was 35.9 ng/mL at 3 hours,
and the average plasma concentration was maintained above 2.5 ng/mL for 5 days in the
animals. No significant difference in the maintenance of analgesia was found at the doses
of 8.9 and 2.2 mg/kg for up to 48 hours after injection, although the drug plasma
concentration and AUC of 8.9 mg/kg dose is significant higher than those of 2.2 mg/kg
dose. This shows that the relationship between drug plasma concentrations and analgesia
response are not linear. In this study, 30.1% MPE can be maintained for 3 days with the
drug plasma concentration of 0.8 ng/mL. The bell-shaped dose response curve may
explain it and has been demonstrated in mice after subcutaneous injection of
buprenorphine hydrochloride.98
2.3.3.4. Typical photographs of the subcutaneous tissue at the injection site after
administration of different formulations in rats and mice
The toxicity and skin irritation studies of citric acid esters including ATEC and
ATBC showed tested citrated were safe to use.95 Although there was absence of irritation
data on TBC, it is reasonable to expect the low or no irritation properties of TBC because
of the structure similarity with ATBC. The injection site views after subcutaneous of the
buprenorphine formulations R1 to R3 and M1 to M3 in rats and mice were similar.
Figure 2-6a shows the subcutaneous injection site of the rat after administration of
buprenorphine formulation R1 at day 5. The figure indicated that no formulation
remained at the injection site at day 5 after a single subcutaneous administration of
buprenorphine formulations prepared with TBC. In addition, no obvious inflammation
was observed in most of tested rats at the injection sites. The sign of mild inflammation
was observed in 2 out of 15 tested rats. Figure 2-6b also indicated that no formulation
remained at the injection site on day 5 after the administration of formulation M2 in mice.
Moreover, no obvious inflammation was observed in mice at the injection sites.
2.2.3.5. Evaluation of toxicity of citric acid esters in rats
Figure 2-7 shows the body weight changes of the rats with time after a single
subcutaneous injection of 200 µL of sterilized citric acid esters (TEC, ATEC, TBC and
ATBC) or normal saline solution. No systemic toxicity or significant body weight change
(P = 0.946, one-way ANOVA) was observed in the rats injected with the citric acid esters
compared to those injected with normal saline. Also no abnormal eating and drinking
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(a) 1.5 mg/kg (Rat) at day 5

(b) 2.2 mg/kg (Mouse) at day 5

Figure 2-6. Typical injection site after subcutaneous administration of
buprenorphine formulation prepared with TBC in (a) rats and (b) mice at day 5.
Doses in the rat and mouse studies are 1.5 mg/Kg and 2.2 mg/Kg, respectively.
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Figure 2-7. Body weight changes of rats after subcutaneous administration of
different citric acid esters or normal saline solution.
Each data point represents an average of four measurements.
Standard deviation of four measurements is presented as error bars.
The P value is 0.946.
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habits were observed. This is in accord with the results of acute and chronic toxicity
studies of TEC, ATEC, TBC and ATBC which indicated that all four tested citric acid
esters would not cause damage to the liver, kidney, lungs and spinal cord for the tested
animals.99,100
2.4.

Conclusions

Oral administration route is the most convenience delivery method for human, but
it, such as putting analgesic in the water for the rodents, runs the risk of inaccurate dosing
and that of degradation due to hydrolysis.101 Therefore methods for analgesic delivery to
rodents are primarily limited to parenteral rather than oral delivery.
Animal welfare regulations require that analgesia should be provided whenever a
procedure is performed or a condition is present that is likely to cause pain. Laboratory
rats and mice are widely used in research and suffer the pain after the surgery. Opioid
analgesics are the primary therapeutic agents used for moderate to severe pain.87
Buprenorphine, butorphanol and morphine are three commonly used opioids.
Buprenorphine had an intermediate analgesic effect and the longest duration (6 to 8 hrs in
rats and 3 to 5 hrs in mice) compared to morphine (2 to 3 hrs) and butorphanol (1 to 2
hrs) in rats and mice.93 The Formulary for Laboratory Animals lists the recommended
buprenorphine dose as 0.01-0.05 mg/kg (SC/IV, 2-3 times daily) for rats and 0.05-0.1
mg/kg (SC, 2-4 times daily) for mice.
Sustained release analgesic provides the advantages of accurate dosing, reducing
the stress of frequent handling and injection, and improving the well-being of research
animals. This hydrophobic delivery system has the advantages of easy preparation,
simple sterilization by filtration, easy administration (including filling and injection), and
cost efficiency. The use of a sustained-release analgesic hydrophobic formulation could
decrease the frequency of handling and increase the welfare of animals at low cost.
The solubility, stability and in vitro dissolution studies were performed in vitro to
screen the hydrophobic vehicles in this study. Buprenorphine in TBC vehicle showed
high solubility, good stability, and desired sustained drug release in vitro performance. In
addition, TBC has been used widely in pharmaceutical products and the toxicity data
supported that TBC was safe to use at tested amount. Therefore it was selected as the
hydrophobic vehicle and tested in rats and mice at different doses. The dosing in PK
studies was based on the calculation and prediction from a desired release profile. The
PK and PD results showed that a simple long-acting controlled release delivery system of
buprenorphine capable of maintaining analgesia in rats and mice for 3 to 5 days after a
single subcutaneous administration was developed in this study.
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CHAPTER 3. A NOVEL IN VITRO DISSOLUTION MODEL FOR OILY
FORMULATIONS: MODEL DESIGN, RELEASE MECHANISM, AND THE
DEVELOPMENT OF LEVEL A IVIVC
3.1.

Introduction

Current United States Pharmacopeia (USP) apparatus for in vitro release testing
was designed mainly for oral and transdermal products. In contrast, there are no standard
regulatory methods for parenteral sustained release products at present.69,70 Over the past
decade, several methods have been attempted to describe drug release from parenteral
products and the current in vitro release methods for parenterals might be divided into
four broad categories: sample-and-separate,69,70 ultrafiltration,70 continuous flow
methods,69,70 and dialysis techniques including rotating dialysis,71 dialysis sac,70 and
microdialysis.70 The advantages and disadvantages of each method were discussed by
Diane J. Burgess70 and Claus Larsen.69 In general, dialysis techniques are considered
feasible for the study of drug release from the solutions and suspensions.102,103 Amongst
these methods, the rotating dialysis cell model has been used to study drug release from
oily depot solutions.71 It offers the advantages of reproducible results and fast distribution
processes. But it has been shown to establish an in vitro-in vivo correlation for just one
particular formulation.104 In addition, commercially available Float A Lyzer® dialysis
tubes can be used as an alternative dialysis model. In contrast to the rotating dialysis cell,
it works at much less intensive stirring conditions, resulting in lower drug transport
rates.105
A successful in vitro dissolution model needs to differentiate the variants within
the appropriate formulations with similar drug release mechanism, and any changes with
respect to process or manufacturing site. Level A IVIVC can be used to set the critical
dissolution specifications and as a surrogate for in vivo bioequivalence.103 As regards to
quality control as well as formulation development purposes,69,106 it is still highly
desirable to a develop suitable in vitro release model for parenteral products with the
characters of Level A IVIVC and elaboration on drug release mechanism. The
development of IVIVC for parenteral products is more difficult than oral dosage forms.
Only a few publications had success on IVIVC for parenteral products107 and very few
examples of IVIVC being developed from more than one formulation.107 In addition, for
most examples in which IVIVC was stated for parenterals, the mathematical models that
describe the drug release have not been provided.107 So far there is no successful in vitro
dissolution method with the character of Level A IVIVC exists at present for parenteral
oily formations. In general, it is accepted that the process of development and validation
of IVVIC for parenterals could follow the same as modified release (MR) oral
products107. The principles of FDA IVIVC MR guidance108 for oral products were used to
develop level A IVIVC for parenterals in this study.
Long-acting buprenorphine controlled release formulations were developed and
tested in this study in order to verify the new dissolution model. The purposes of this
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study are to design, develop and validate the novel dissolution model with the character
of level A IVIVC and to elucidate the drug release mechanism of this model.
3.2.
3.2.1.

Materials and Methods

Materials

Buprenorphine was obtained from Diosynth Inc. (Morrisville, NC). Tributyl
citrate (TBC) and acetyltributyl citrate (ATBC) were obtained from Morflex, Inc.
(Greensboro, NC). Heparinized Microvette tubings (Microvette CB 300 LH) were
purchased from Sarstedt (Newton, NC). Sodium dodecyl sulfate (SDS) and acetonitrile
(ACN) were purchased from Sigma-Aldrich (St. Louis, MO).
3.2.2.

Animals

Approximately 300 g Sprague Dawley male rats (Charles River Labs,
Wilmington, MA) were used in this study. The animals were randomly assigned and
group-housed in polycarbonate caging with ad libitum access to food and water. All
animal experiments were conducted according to protocols approved by the Institutional
Animal Care and Use Committee (IACUC).
3.2.3.

Softwares

Excel 2003 (Microsoft Office, Redmond, WA), WinNonlin (Pharsight
Corporation, Cary, NC), SPSS 17.0 (SPSS Inc., Chicago, IL), and Stella 9.0 (isee
systems, Inc., Lebanon, NH) were used to process the data generated in this study.
3.2.4.

Analytical methodology for in vitro and in vivo studies

3.2.4.1. Analytical methodology for in vitro studies – HPLC/fluorescence analysis
HPLC method validation developed to quantitate buprenorphine in samples
obtained from in vitro studies has been discussed in Chapter 2. Briefly, discovery C-18
column (2.1 x 100 mm) (Supelco, Bellefonte, PA) was used. The mobile phase was
composed of a mixture of 51 mM KH2PO4 buffer and acetonitrile (ACN) (45:55, v/v)
with the final pH 6.65 adjusted by 10N NaOH solution. The oven temperature was 40°C
and the flow rate was 0.3 mL/min. The total run time was 6 minutes. Buprenorphine was
detected with fluorescence detector at λExitation = 292 nm and λEmission = 350 nm.
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3.2.4.2. Analytical methodology for in vivo studies – LC-MS/MS method
Validation of LC/MS/MS method has been discussed in Chapter 2 to quantify the
concentrations of buprenorphine in plasma samples obtained from in vivo studies.
Briefly, LC/MS/MS system consisted of Shimadzu HPLC systems, a HILIC silica
column (5 m, 150 × 4.6 mm) with a guard column (10 × 2.1 mm) (Waters Inc., Milford,
MA), and API 4000 tandem triple quadrupole mass spectrometer (Applied Biosystems,
Foster City, CA). Solution A (ACN : water : formic acid (4.95:95:0.05, v/v/v) with 2 mM
ammonium formate) and solution B (ACN : water : formic acid (95:4.95:0.05, v/v/v) with
2 mM ammonium formate) were used. The time program of the gradient method started
with 90% of Solution B followed by decreasing linearly from 90% to 40% within 3.5
minutes. Then it immediately increased to 90% and maintained at 90% for 2 minutes.
The concentration of Solution B was further decreased linearly from 90% to 40% within
0.5 minute, linearly increased to 90% within 0.5 minute and maintained at 90% for 4
minutes. The column was operated at room temperature and the flow-rate of the mobile
phase was 0.5 mL/min. Ion transition of 468.3 to 468.3 and 472.3 to 472.3 were selected
for buprenorphine and buprenorphine-D4 detection, respectively.
3.2.5.

Formulation preparation

An appropriate amount of buprenorphine base powder was accurately weighed
and dispersed into an appropriate amount of solvent(s) (Table 3-1) in 20 mL glass
scintillation vials. The subsequent suspension was sonicated under 25ºC until all drug
powder was dissolved. The final solution was obtained by filtering the above solution
through a 0.22 μm syringe filter in a sterile hood and then sealed. The drug concentration
was verified by HPLC method. Formulation 3-1b and 3-2 were tested in rats for IVIVC
development and all prepared formulations were tested in the designed dissolution model
for different purposes.
3.2.6.

In vitro tests

3.2.6.1. In vitro dissolution model design
When the partition coefficient of the API is below approximately 10,000,109 it is
expected that drug molecules transport from the injection site to the systemic circulation
by two steps after intramuscular or subcutaneous administration of oily solutions.103 Drug
molecules (1) diffuse out of the oily vehicle into the aqueous tissue fluid followed by (2)
transporting through the tissue fluid to the systemic circulation. Except in-situ forming
gels,103 partition between the oily vehicle and the aqueous fluids is the rate limited step
and absorption rate has little dependence on vehicle viscosity.103,110 The cylinder-inbasket (CIB) apparatus (Figure 3-1) was designed and developed based on this drug
absorption mechanism, The CIB apparatus consists of a cylinder, a USP standard 1-Liter
vessel, a USP standard cylindrical basket (40-mesh basket in this study), a USP standard
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Table 3-1.

The formulations tested in the dissolution model development study.

Formulation
3-1a
3-1b
3-1c
3-1d
3-2
3-3a
3-3b

Solvent(s)
TBC
TBC
TBC
TBC
ATBC
TEC:ATEC:TBC 1:1:1 (v/v/v)
TEC:ATEC:TBC 1:1:1 (v/v/v)
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Concentration of
Buprenorphine
% (w/w)

In Vitro

0.3
0.5
1.5
3
0.5
0.5
1.3

x
x
x
x
x
x
x

Tested in

Dose

In Vivo

(mg/kg)

x

3

x

3

x

3

Cover
1-Liter vessel
Dissolution medium

Diameter

Paddle

5.00 mm
Height

Cylindrical basket (40 mesh)
Loaded formulation
Cylinder

20.00 mm

(a)
Cylinder #
Height (mm)
Diameter (mm)

Figure 3-1.

(b)
#1
12.3
12.5

#2
12.3
15.0

#3
12.3
17.5

#4
24.6
12.5

#5
24.6
15.0

#6
24.6
17.5

(a) Cylinder and (b) cylinder-in-basket (CIB) apparatus for in vitro dissolution study.
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paddle, a USP standard dissolution apparatus (Hanson SR8PLUS Dissolution Test
Stations, Hanson Research Corp.) and an AutoPlus Autosampler (Hanson Research
Corp.). There are two compartments in this CIB model: the small compartment inside the
basket and the bulk compartment outside the basket. The solution in the small
compartment mimics the body fluid and the media in the bulk compartment mimics the
systemic circulation. After loading the formulation into the cavity of the cylinder, the
drug molecules were assumed to diffuse into the small compartment followed by
transporting to the bulk compartment. The basket was designed to protect the oily vehicle
out of the vigorous convection in the bulk compartment and mimic the biological barrier.
During the experiment, the oily vehicles were assumed to maintain the constant surface
area which benefited the mechanism study. Six different Teflon cylinders (Figure 3-1)
were designed, prepared and tested in this study for different purposes. Except the studies
to explore the effect of cylinder surface area and height, the cylinder #5 was used in the
rest studies.
3.2.6.2. Partition coefficients
The partition coefficients of buprenorphine between the oily vehicles and
dissolution medium were performed in triplicate. According to preliminary studies,
solutions of drug in aqueous phase-saturated oily vehicles were allowed to equilibrate
with the oil phase-saturated aqueous buffers in the incubator at 100 rpm and 37 ± 0.5°C
for at least 48 hr. Drug concentrations in the aqueous phase were directly measured by a
validated HPLC method. The drug content in the oily phase was determined by diluting
100-fold with ACN : water (70:30, v/v), followed by drug concentrations analysis using
HPLC method. The partition coefficients were calculated according to the Equation 3-1.
P

C oil
C aq

(Eq. 3-1)

where Coil and Caq represent the drug concentration in the oily phase and the aqueous
phase at the equilibrium state, respectively.
3.2.6.3. Short-term stability studies
Short-term stability of buprenorphine in the dissolution medium at 25°C and 40°C
was evaluated within 5 days. The drug concentration in the tested samples was equal to
the value of the maximum amount of drug in tested formulation dissolved in 900 mL
dissolution medium. The sample solution in a 20 mL scintillation vial wrapped securely
with para-film was stored in ovens at 25 ± 0.5 °C and 40 ± 0.5 °C. The study was
performed in triplicate at each time point. Drug concentration in the sample at time 0 was
used as the reference. The drug content in the samples was tested at predetermined time
points using HPLC method. The length of each drug stability study was different and the
last time point of the stability study was selected as same as that in dissolution study.
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3.2.6.4. In vitro release studies
The tested formulation was loaded into the cavity of the cylinder followed by
covering with the USP basket (40-mesh). The cylinder-in-basket kit was then transferred
to the center bottom of a 1-Liter dissolution vessel. The dissolution medium was carefully
loaded into the vessel at the rate of 7 mL/sec using a modified Hanson Media Mate
(Hanson Research Corp.). The paddle blade stirrer was then inserted into the apparatus
and located on the top of the basket. The distance between the top of the basket and the
bottom of paddle blade was adjusted. Except the study on the effect of paddle distance,
the distance was set at 2 cm. The vessels were covered with a special designed lid and
tightened with laboratory para-film in order to avoid evaporation of the medium. The
paddle and dissolution medium were varied for different purposes and will be specified in
the discussion section. Experiments were conducted by triplet. During the dissolution
experiment, samples (1 mL) in bulk dissolution medium were withdrawn from each
vessel at predetermined time points. After sampling, 1 mL blank dissolution medium was
refilled into the bulk dissolution medium. Drug content of the samples was measured by a
validated HPLC method. The pH of dissolution medium was adjusted by hydrochloride
and sodium hydroxide. The ion strength of dissolution medium calculated by Debye–
Hückel equation was adjusted by sodium chloride and kept at 0.13. The percentage of
drug released from the solutions was calculated according to the Equation 3-2.
n

% Re leased 

Vs   C n 1  Vb  C n
n 1

M total

100 %

(Eq. 3-2)

where Vs is the sampling volume (1 mL in this study) at different time points and Vb is
the volume of total dissolution medium; Cn and Cn-1 represent the drug concentration in
sample n and n-1; Mtotal is the total amount of drug in the tested formulation.
3.2.6.5. Discriminating power of the dissolution test
The drug release profile can be predicted from proposed equation. The
discriminatory power of the dissolution test was used to evaluate the difference between
predicted and experimental dissolution profiles. The predicted and experimental
dissolution profiles were compared using two methods: the difference factor (f1) and the
similarity factor (f2). The f1 factor111 measures the percent difference between two curves
over all time points and can be calculated by Equation 3-3. The value of f1 factor is zero
when the test and drug reference profiles are identical and proportionally increases as the
dissimilarity of the two dissolution profiles increases.
 n
  Rt  Tt

f1    t 1 n
  R
t
 
t 1
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  100




(Eq. 3-3)

where n is the number of time points, Rt and Tt are the percent dissolved of the reference
and test product, respectively, at each time point. The predicted dissolution profile was
used as the reference.
The f2 factor111 is a logarithmic reciprocal square root transformation of the sum
of squared error and measures the differences between the test and the reference products
over all time points and can be calculated by Equation 3-4. This factor is 100 when the
test and reference profiles are identical and decreases as the similarity of the two
dissolution profiles decreases.
 0 .5

   1  n

f 2  50  log  1     ( Rt  Tt ) 2   100 

   n  t 1


3.2.7.

(Eq. 3-4)

IVIVC development

3.2.7.1. In vitro studies for IVIVC development
The in vitro drug release of formulation 3-1b and 3-2 were conducted in CIB
dissolution model. The loading volume (~ 0.2 mL) of the oily formulation was the same
with the injection volume in rat studies. The mixture of 15% (v/v) n-propyl alcohol (nPA)
in Phosphate buffered saline (PBS) solution with 0.15% (w/v) sodium dodecyl sulfate
(SDS) at pH6.0 was selected as the dissolution medium. The paddle speed was set at 50
rpm and cylinder #5 was utilized. The amount of drug release at different time point, Mt,
was evaluated by validated HPLC method. The linear correlation was explored by SPSS
software. The percentage drug release was calculated by Excel.
3.2.7.2. In vivo evaluation of buprenorphine solutions in rats for IVIVC development
FDA recommends that two or more formulations with different drug release rate
should be used to develop level A IVIVC.108 The data generated in rat studies after
subcutaneous injection of formulation 3-1b and 3-2 (Table 3-1) were tested in this study.
Formulation 3-1b or 3-2 (~ 200 µL) were subcutaneously administered into male Sprague
Dawley (SD) rats (four rats/group) using 23-gauge needle and the syringes were weighed
before and after administration. The exact weight of the buprenorphine solution
administered was calculated based on the weight. Blood samples (~ 0.2 mL) were
withdrawn by saphenous vein and collected in heparinized Microvette tubings at
predetermined time points within two weeks. The collected blood samples were
immediately centrifuged at 14K rpm for 7 min and plasma samples were stored at -20°C
until further analysis. The plasma samples were processed and analyzed for drug content
using the validated LC/MS/MS method. The average plasma concentration at each time
point was reported.
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3.2.7.3. Bioavailability of buprenorphine in rats
An intravenous study was tested in rats to determine the PK parameters of
buprenorphine at the dose of 0.05 mg/kg and described in Chapter 2. The PK parameters
(Ke, AUC0-t, and AUC0-∞) were calculated by using WinNonlin non-compartment model.
The terminal elimination rate constants (Ke) after i.v. administration were estimated with
least-squares regression of values in the terminal log-linear region of plasma
concentration–time curves. The areas under the curve (AUC) from time zero to last
sampling time (AUC0-t) after drug administration were determined by the logarithmic
trapezoidal rule. The area under the curve from time zero to infinity (AUC0-∞) was
calculated as AUC0-t +Ct/Ke, where Ct is the last detected plasma concentration and t is
the time.
Buprenorphine saline solution was subcutaneously injected into four male
Sprague Dawley (SD) rats at the dose of 0.05 mg/kg. The syringes were weighed before
and after subcutaneous administration and the exact weight of the buprenorphine solution
administered was calculated based on the weight. Blood samples (~ 0.2 mL) were
withdrawn from the saphenous vein with a 25 gauge needle and kept in heparinized
Microvette tubings at 0, 5, 15, and 30 min, and 1, 2, 4, 6 and 12 hr.
The bioavailability (F) was calculated by Equation 3-5 after subcutaneous
injection of buprenorphine saline solution at the dose of 0.05 mg/kg.
F

AUC SC / DSC
AUC i.v. / Di.v.

(Eq. 3-5)

where AUCSC, AUCi.v. and DSC, Di.v. represent the AUC and dose after the subcutaneous
or intravenous injection.
3.2.7.4. Deconvolution method
The fraction of drug absorbed in vivo (Fa) after subcutaneous injection of
formulation 3-1b and 3-2 was determined using the Loo-Reigelman method by Equation
3-6.112 The model-dependent pharmacokinetic parameters of K10, K12 and K21 used in the
calculation were calculated using WinNonlin two-compartment model. The deconvolution was accomplished on a spread-sheet in Excel.

% Fa 

 X A t
 X A 

C t  k 10 AUC
 100 

t
0



k 10 AUC


0

 X P t
VC

 100

(Eq. 3-6)

where (XA)t, (XA)∞ and (Xp)t represent the amount of drug absorbed at time t, the amount
of drug ultimately absorbed, and the amount of drug in the peripheral compartment at
time t. Ct, K10 and Vc represent the plasma concentration at time t, the apparent first-order
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elimination rate constant of the drug from the central compartment, and the apparent
volume of the central compartment. AUC0-t and AUC0-∞ represent area under the plasma
concentration-time curve from time zero to the last measurable concentration and from
time zero to infinity.
After the calculation of Fa, the drug release amount at different time point in vivo
was calculated based on bioavailability and total amount injected. The linear correlation
between Ln[Mtotal /( Mtotal-Mt)] and time was explored by SPSS software, where Mtotal is
the total amount of the drug absorbed.
3.2.7.5. IVIVC development and validation
The data generated in the in-vitro and in-vivo studies and linear relationship
between Fdiss and Fa of tested formulations were used in internal and external validation.
The relationship between mean percent of drug dissolved in in-vitro dissolution study
(Fdiss) and the mean fraction of drug absorbed in-vivo (Fa) was examined in this study.
The Fdiss was determined using the CIB dissolution testing method and Fa was
determined by Loo-Riegelman method. The linear regression analysis was applied to
explore the relationship between Fdiss and Fa. The values of coefficient of determination
(R2), slope and intercept were calculated, respectively.
The internal predictability of the IVIVC was evaluated by comparing predicted
plasma profiles with the actual plasma profiles of formulation 3-1b and 3-2. The
prediction of the plasma drug concentration and AUC was accomplished using IVIVC
toolkit of Stella 9.0 (isee systems, Inc.) software.113 The pK parameters of buprenorphine
in rats, the linear relationship generated in IVIVC development, and the mean in-vitro
dissolution data (Fdiss) of each examined formulation were input into the software. The
observed and IVIVC model-predicted Cmax and AUC values for each formulation were
used to access the predictability of the correlation. The percent prediction errors (%PE)
for Cmax and AUC were used to evaluate prediction and calculated by Equations 3-7 and
3-8.108

% PEmax 

% PE 

C max (obs)  C max ( pred )
 100
C max (obs)

AUC (obs)  AUC ( pred )
AUC (obs)

 100

(Eq. 3-7)

(Eq. 3-8)

where Cmax(obs), Cmax(pred) and AUC(obs), AUC(pred) are the observed and IVIVC
model predicted maximum plasma concentrations and AUC, respectively.
The external validation was accomplished by comparing predicted plasma profiles
with the actual plasma profiles of formulation 3-3a. The pK parameters of buprenorphine
in rats, the linear relationship generated in IVIVC development, and the mean in-vitro
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dissolution data (Fdiss) of the formulation were input into Stella to predict the drug release
profile. The same dissolution conditions were applied in in-vitro study. The percent
prediction errors (%PE) for Cmax and AUC were also used to evaluate prediction.
3.3.
3.3.1.

Results and Discussion

In vitro studies

Unlike the solid formulations, the surface of the parenteral formulations is easy to
be disrupted by other factors, such as agitation of the dissolution medium. The variance
of the surface of the parenteral formulations is one of the major reasons caused the
unpredictable drug release. According to the preliminary studies, the high variance could
be generated on the steps of the loading of the dissolution medium and by the agitation of
the dissolution medium. In this study, the Hanson Media Mate (Hanson Research Corp.)
was used to load the dissolution media at the rate of 7 mL/sec. A special designed tubing
was used to conduct the medium solution to the wall of the vessel during the loading
process. In addition, the agitation generated by paddle in the bulk solution can cause the
high variation of the surface of liquid formulation during the dissolution test. Therefore
the effect of paddle position, paddle speed, and cylinder diameter were investigated by
formulation 3-1c and dissolution medium of 10% (v/v) iso-propyl alcohol in PBS with
0.05% SDS at pH 7.4 in this study.
3.3.1.1. Effect of paddle position

One of the major problems of in vitro dissolution model development for the
parental formulations is the high variation generated during the experiment. In this CIB
dissolution model, the basket was designed to protect the liquid formulation out of the
effect by the agitation of the dissolution medium. The USP standard 40-mesh basket is
selected to protect the liquid formulation. The distance (0.5 and 3 cm) between the bottle
of paddle blade and the top of the basket was tested on the condition of high agitation
(150 rpm) to explore the effect of the paddle position. Two cylinders, #5 and #6, with
different diameter (15.0 mm and 17.5 mm) were tested. If the 40-mesh basket couldn’t
protect the liquid formulation, the high variance was expected and the drug release rate
tested in two different conditions with different distances should vary because of the
different convection environment at the liquid/medium interface.
Figure 3-2 shows the release profiles of buprenorphine from oily vehicle in the
CIB dissolution model by changing the paddle location. The f2 values are 81.2/87.4 and f1
values are 12.4/6.1 for the results generated from cylinder #5 and #6, respectively. It
indicates that there is no significantly difference of the dissolution rate for the test
formulation by changing the paddle position at 150 rpm. The drug release rate is not
affected by the vigorous convection outside the basket under the tested formulation and
conditions. In addition, the less variance of dissolution results using CIB model was
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Amount Released (ug)

Paddle Speed: 150 rpm
Diameter of cylinder: 15 mm
Distance: Varies
3 cm
0.5 cm

1000
800
600
400
200
0
0

24

48

72

96

Amount Released (ug)

Time (hr)

Paddle Speed: 150 rpm
Diameter of cylinder: 17.5 mm
Distance: Varies

1000

3 cm

800

0.5 cm

600
400
200
0
0

24

48

72

96

Time (hr)

Figure 3-2. The effect of paddle position on the release amount of buprenorphine
in CIB dissolution model.

n =3.
Data are presented as mean ± SD (g).
Tested formulation was formulation 3-1c.

59

observed, which indicated that the 40-mesh basket can protect the oily phase from the
vigorous convection in the bulk solution.
3.3.1.2. Effect of paddle speed

The agitation of the medium could be the other reason which causes the high
variation in the CIB model, so the effect of paddle speed was explored at the levels of
100 and 150 rpm. Figure 3-3 shows that drug release rate is noticeably faster at 150 rpm
than that observed at 100 rpm with low variance. This indicates that drug release rate
increases at the higher speed. In the CIB dissolution model, it is expected that drug
molecules first diffuse into the small compartment and then diffuse out from small
compartment to the bulk compartment. Different paddle speed will affect the convection
flow in the bulk media. Vigorous agitation can help drug concentration to achieve the
equilibrium between the media inside and outside of the basket. Higher paddle speed is
expected to give a more vigorous agitation and to achieve equilibrium in a shorter time,
resulting in higher concentration gradient. Therefore, the drug concentration in the bulk
media will achieve equilibrium faster and drug release at higher paddle speed gives faster
release rate.
3.3.1.3. Effect of cylinder height

Two different sets of cylinders were used. The first set (cylinder #2 and #3) has
the height of 12.3 mm with the diameter of 15 mm and 17.5 mm. The second set
(cylinder #5 and #6) has the height of 24.6 mm with the different diameter. Other
parameters of the cylinder are the same and the paddle speed during the dissolution study
was set at 100 rpm. Figure 3-4 shows that the amount of drug release using the 12.3 mm
height cylinder is faster than that using the 24.6 mm height cylinder. The volume of the
cylinder with the height of 12.3 mm is less than that of the cylinder with the height of
24.6 mm. When 12.3 mm height cylinder is covered with the basket, the volume of
dissolution medium inside the basket (volume of small compartment in CIB model) is
relatively larger than that using 24.6 mm height. When the same amount of drug is
diffused out of the oil vehicle into the small compartment, the drug concentration in the
small compartment will be relatively lower using 12.3 mm height cylinder compared to
that using 24.6 mm height cylinder if the drug release rate is the same. And the
concentration gradient will be relatively higher by using 12.3 mm height cylinder.
Therefore the height of cylinder could affect the drug release rate and the cylinders with
different height should be carefully selected for different purposes.
3.3.1.4. Effect of diameter of cylinder

After loading the oily formulation into the cavity of the cylinder, the surface area
between aqueous phase and oily vehicle is assumed to the surface area of the cylinder
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Amount Released (ug)

Diameter of cylinder: 15 mm
Paddle Speed: Varies
100 rpm

1000

150 rpm

800
600
400
200
0
0

24

48

72

96

Time (hr)

Amount Released (ug)

Diameter of cylinder: 17.5 mm
Paddle Speed: Varies
1000

100 rpm

800

150 rpm

600
400
200
0
0

24

48
Time (hr)

72

96

Figure 3-3. The effect of paddle speed on the release amount of buprenorphine in
CIB dissolution model.

n =3.
Data are presented as mean ± SD (g).
Tested formulation was formulation 3-1c.
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Diameter of Cylinder: 15 mm
Height (H) of Cylinder: Varies
Amount Released (ug)

800

H=12 mm
H=24 mm

600
400
200
0
0

24

48

72

96

Time (hr)

Diameter of Cylinder: 17.5 mm
Height (H) of Cylinder: Varies
Amount Released (ug)

800

H=12 mm
H=24 mm

600
400
200
0
0

24

48
Time (hr)

72

96

Figure 3-4. The effect of cylinder height on the release amount of buprenorphine
in CIB dissolution model.

n =3.
Data are presented as mean ± SD (g).
Tested formulation was formulation 3-1c.
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cavity. The cylinder #1, #2 and #3 with different surface area were used in this test and
the paddle speed was set at 100 rpm. The cylinder diameter aggrandizement from
cylinder #1, #2 to #3 also increased the exposed surface area between oil formulation and
dissolution medium. Figure 3-5 shows that drug release rate increases with the cylinder
surface diameter. By increasing the surface area of cylinder, more drug molecules can
diffuse out of oily phase to the aqueous phase at unit time. According to the Equation
3-9, the slope was calculated by plotting Ln[C0V0/(C0V0-Mt)] versus time. The
experimental release rates (Kapp) for each cylinder are 0.0321, 0.0463 and 0.0625 day-1,
respectively, with the ratio of 0.69:1:1.35. The ratio of the surface area (πr2) of three
cylinders is 0.69:1:1.36. The result is consistent with the Equation 3-9, which indicates
the release rate is proportional to the surface area when there is no change in the other
parameters. The derivation and details of Equation 3-9 will be discussed in Section
3.3.2.1.
Ln (C 0V0 )  Ln (C 0V0  M t ) 

DS
KS
t
t  K app t
hV0 P
V0 P

(Eq. 3-9)

where C0 and V0 represent initial drug concentration and initial volume of loaded
formulation. Mt represents the amount of drug at different time in aqueous phase. D, h
and S represent diffusion coefficient, the length of diffusion layer, and oil–water interface
area. The K is the ratio of D divided by h and Kapp is the apparent rate constant.
3.3.2.

Drug release mechanism

Drug release mechanism in the CIB dissolution model was explored in this study.
The in vitro CIB model was designed to mimic the in vivo drug absorption mechanism
after subcutaneous or intramuscular injection. There are two compartments in the CIB
model. The small compartment (1) inside the basket and the large compartment (2)
outside the basket mimic the body fluid at the injection site and the systemic circulation,
respectively. In order to explore drug release mechanism in CIB model, the assumption
was made that drug molecules in the oily vehicle diffused into the aqueous dissolution
medium and the kinetic equilibrium can be achieved instantly at the interface between the
oily vehicle and dissolution medium, although the equilibrium between the oily phase
and the bulk solutions may take a few hours to reach in the partition coefficient test.
Therefore the drug concentration at the interface between the oily vehicle and dissolution
medium can be calculated by Equation 3-10.
P

C oil
C aq



C toil
C taq  int er

(Eq. 3-10)

where Ctoil and Ctaq-inter are the drug concentration at different time points in the oily
phase and the aqueous dissolution medium at the oil-water interface, respectively. P is the
partition coefficient between oily phase and dissolution medium. Both Ctoil and Ctaq-inter
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Figure 3-5. The effect of cylinder diameter on the release amount of
buprenorphine in CIB dissolution model.

D is the cylinder diameter.
n =3.
Data are presented as mean ± SD (g).
Tested formulation was formulation 3-1c.
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are the variables, but the ratio P is a constant. The partition coefficient of the drug
between oily vehicle and dissolution medium is calculated by measuring the drug
concentration in two phases at equilibrium state. Based on the assumption and the
concept of Whitney-Noyes equation, the overall drug release in this dissolution model
can be calculated from Equation 3-9.
3.3.2.1. Derivation of mathematical Equation 3-9

Noyes-Whitney equation describes the drug release from the solid dosage form,
while drug release from the oily vehicle is more complicated. In the solid dosage form,
Noyes-Whitney equation shows that concentration gradient is the driving force for drug
to diffuse into the aqueous phase. In the sink condition, the drug concentration in the
aqueous phase may be ignored, otherwise it can’t. Drug release from oily phase to
aqueous phase in CIB dissolution model is the diffusion-controlled process and can be
illustrated as following.
C 0t
C1t

C2t

Oily
phase

h

Aqueous
phase

where C0t, C1t, and C2t represent drug concentration in oily phase, at the interface, and in
the bulk aqueous phase at different time points.
According to aforementioned assumption, drug molecules in the oily vehicle
diffuse into the aqueous dissolution medium and the kinetic equilibrium can be achieved
instantly at the interface and the drug concentration at the interface between the oily
vehicle and dissolution medium can be calculated by Equations 3-1 and 3-10.
During the drug release process, oily vehicle in the formulation could (1) dissolve
or (2) partly dissolve in the aqueous phase. Both conditions were considered in the
development of the drug mechanism.
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3.3.2.1.1. Oily phase doesn’t dissolve in aqueous phase
Under the sink condition
C1t 

C 0 t 1 C 0V0  M t
M
1
 (
)  (C 0  t )
P
P
V0
P
V0

dM 

M
DS
DS
DS
C1t dt 
(C1t  C 2t ) dt 
(C 0  t ) dt
h
h
Ph
V0

where C0 and V0 are constants and represent initial drug concentration and initial volume
in the oily phase. Mt represents the amount of drug at different time pints in aqueous
phase.
After solving the differential equation, following Equation 3-9 was derived to
describe the drug release from insoluble oily vehicle to the aqueous solution in the sink
condition.
DS
t  Ln(C0V0 )  Ln(C 0V0  M t )
hV0 P

Under the non-sink condition
dM 

DS
(C1t  C 2t ) dt
h

C1t  P 1C 0t  P 1 (C 0 
C 2t 

Mt
)
V0

Mt
Va

where Va is the volume of the aqueous phase.
After solving the differential equation, Equation 3-11 is obtained.

Ln( P 1C0V0Va )  Ln[ P 1C0V0Va  ( P 1Va  V0 )M t ]
DS
t
hV0Va
P 1Va  V0

(Eq. 3-11)

The V0 is usually 0.2 mL and Va is 900 mL in this study. It indicates when P-1Va
>> V0 or P is less than 4500, Equation 3-11 can be simplified to Equation 3-9.
DS
t  Ln(C0V0 )  Ln(C 0V0  M t )
hV0 P

when P-1Va >> V0
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3.3.2.1.2. Oily phase partially dissolves in aqueous phase
If oily phase partially dissolves in aqueous phase, V0 will not be the constant and
the release of the oily vehicle will affect the release of drug. The release of oil and drug
molecules is considered as independent. The release of oil will decrease the volume of
oily vehicle and increase the drug concentration in the oily phase. Therefore the drug
release rate will increase. According to the Noyes-Whitney equation, the release of oily
vehicle can be described as:
M ' D' S '
dM ' D' S '
D' S '

(Cs 'C2 ' ) 
(Cs ' t ) 
(Va Cs ' M t ' )
dt
h'
h'
Va
Va h'
 Ln(Va Cs ' M t ' )  Ln(Va Cs ' )  
 M t '  Va Cs ' (1  e



D 'S '
t
Va h '

D' S '
t
Va h'

)

where Cs’, C2’ represent saturated concentration of oil and concentration of oil in the
aqueous phase, respectively. Mt’ represents the amount of oily vehicle at different time in
aqueous phase. D’, h’ and S’ represent diffusion coefficient, the length of diffusion layer,
and oil-water interface area of the oil vehicle.
Then the release of drug molecules can be described as:
dM 

M
DS
DS 1 C 0V0  M t
DS
(C1t  C 2t )dt 
[P (
)  t ]dt 
( P 1C 0V0Va  P 1 M tVa  M tV0t )dt
h
h
V0t
Va
hV0tVa



DS
1
dM 
dt
1
hV0tVa
P C 0V0Va  P Va M t



1
DS
dM 
dt
C 0V0  M t
hPV0t

when P 1Va  V0t

1

where V0t is the volume of oily phase at different points.

V0t 

M total ' M t ' M total 'VaCs ' (1  e

d'
d'



D 'S '
t
Va h '

)

DSd '
hPVa Cs '
DSd '
1
1
dt 
dt
dM 
D 'S '
D 'S '
t


t
C0V0  M t
hPVa C s ' M total '
M total '
Va h '
Va h '
 (1  e
 1)  e
)
(
Va C s '
Va Cs '

(Eq. 3-12)

where d’ is the density of oil and Mtotal’ represents the total amount of oily vehicle.
After dissolving Equation 3-12, Equation 3-13 can be obtained.
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D 'S '

Dd ' V a h '
V C ' ( M total 'V a C s ' ) e V a h '
Ln ( C 0 V 0 )  Ln ( C 0 V 0  M t ) 
Ln a s
hPD ' ( M total 'V a C s ' )
M total '

t

(Eq. 3-13)

If the oily vehicle is insoluble (Cs’ ≈ 0) or partly soluble (Mtotal’ >> VaCs’) in the
aqueous phase, Equation 3-13 can be simplified to the following Equation 3-9.
Ln (C 0V 0 )  Ln (C 0V 0  M t ) 

DS '
DS
t
t
hPV 0
hPV 0

Oily vehicles usually are insoluble in the aqueous phase and the tested oily
vehicle in this study, TBC, is insoluble in water. Although the increasing amount of
surfactant or cosolvent and the adjustment of pH in the dissolution medium could
increase the solubility of oily vehicle in the medium. But until the majority of the oily
vehicle is insoluble in the aqueous phase, Equation 3-9 can be applied. Therefore,
Equation 3-9 is used to describe the drug release from TBC formulations in this study.
3.3.2.2. Verification of mathematical equation

There are seven parameters in Equation 3-9. Amongst them, Mt is the variable
and can be measured by HPLC. Partition coefficient, P, can be calculated by measuring
drug concentration between dissolution medium and oily vehicle at equilibrium state. K
is related to the diffusion coefficient, D, and the length of diffusion layer, h. For the given
formulation and dissolution medium, the P and K could be considered as the constant. In
order to verify this equation, the rest parameters, C0, V0, and/or S, were challenged. The
verification procedures of Equation 3-9 were performed as follows.
Step 1. Run the dissolution test and calculate K for the given oily vehicle and
dissolution medium.
1. Measure the partition coefficient P between oily vehicle and dissolution
medium at equilibrium state
2. Select the cylinder and calculate the S of the cylinder cavity
3. Prepare the oily formulation and calculate the initial drug concentration C0
4. Weigh the formulation after loading it into the cavity of the cylinder and then
calculate the formulation volume V0.
5. Run the dissolution test and measure the released drug amount at
predetermined time points, Mt.
6. Calculate the K from the slope Kapp by plotting Ln(C0V0)-Ln(C0V0-Mt) versus
time.
Step 2. A new in vitro test was conducted using the same oily vehicle, dissolution
medium, and other dissolution conditions as the initial dissolution study in step 1. Since
the dissolution conditions didn’t change, the initial and new dissolution study should
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share the same K value which was calculated from initial dissolution study. From the
calculated K, the amount drug release could be predicted by challenging variables, C0,
V0, and/or S, and calculated by Equation 3-14 derived from Equation 3-9. The predicted
results were compared with the experimental data. The variance between experimental
and predicted data was compared by calculating f1 and f2 values.
M t  C0V0 (1  e



KS
t
V0 P

)

(Eq. 3-14)

The in vitro release studies were carried out at 37 ± 0.5 °C using the CIB model
and the dissolution medium of 10% (v/v) iso-propyl alcohol (IPA) in PBS at pH 7.4 was
used in this study. The distance between the top of the basket and the bottom of paddle
was set at 2 cm. The loading amount of the formulation was about 210 ± 5 mg. The
volume of dissolution medium is 900 mL. Other parameters, such as cylinder # and
paddle speed, varied in studies for different purposes and will be specified in the each
section.
3.3.2.2.1. Effect of different surface area (S)
In order to verify the effect of different surface area (S) in the equation, TBC
formulation 3-1c was tested in this study and cylinder #2 (cylinder diameter 15.0 mm)
was used in the initial in vitro dissolution study to calculate K. From this calculated K,
the amount of drug release from cylinder #1 and #3 with different S could be predicted.
The predicted drug release data from calculated K was compared to the experimental data
generated from cylinder #1 (cylinder diameter 12.5 mm) and #3 (cylinder diameter 17.5
mm). The paddle speed was set at 100 rpm. The drug concentration at different time
points was detected by HPLC method.
By plotting Ln(C0V0)-Ln(C0V0-Mt) vs. time (Figure 3-6a), the slope Kapp is
0.0463 day-1. The measure P between TBC and dissolution medium is 4549. So
calculated K is 0.64 cm·hr-1. Cylinder #1 and #3 were used to test real time drug release
and compared to the predicted drug release data (Figure 3-6b1 and 3-6b2). In terms of
percentage release, the dissimilarity/similarity factor f1 and f2 values were 11.3/95.3 for
cylinder #1 and 7.2/92.8 for cylinder #3. The results indicate that the Equation 3-9 can
be applied to predict the drug release from tested oily vehicle by changing the cylinder
with different diameter.
3.3.2.2.2. Effect of changing several parameters simultaneously
Equation is verified only when the all the parameters in it can be challenged. In
order to test the effect of changing several parameters simultaneously to the Equation
3-9, formulation 3-1a with the concentration of 3.2 mg/mL (0.3%, w/w) was tested in the
initial dissolution study to calculate K. The loading amount was about 210 ± 5 mg and
the cylinder #5 with the diameter 15 mm was used. The drug concentration at different
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Figure 3-6. (a) The release profile of buprenorphine from formulation 3-1c, and
predicted data and experimental data generated from (b1) cylinder #1 and (b2) #3.
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time points was detected by HPLC method. By plotting Ln(C0V0)-Ln(C0V0-Mt) vs. time
(Figure 3-7a), the slope Kapp is 0.056 day-1. The measured P is 4549 between TBC and
dissolution medium. The calculated K is 1.24 cm·hr-1. From the calculated K, the amount
drug release was predicted using the Equation 3-9 by changing the parameter(s) of C0,
V0, C0 &V0, C0 & S, and C0, V0 & S, simultaneously.
The effect of C0 was explored by predicting the drug release from the
formulations 3-1c and 3-1d with different concentration (1.5% and 3%). Figure 3-7b1
and 3-7b2 showed the predicted drug release amount by time and the experimental data.
In terms of percentage release, the f2/f1 values were 83.5/14 and 86.9/11.9 for
formulation 3-1c and 3-1d, respectively.
The effect of C0 and V0 simultaneously was explored by predicting the drug
release from the formulation 3-1d with the drug concentration (3%) and loading volume
(~ 0.27 mL). Figure 3-7c showed the predicted drug release amount by time and the
experimental data. In terms of percentage release, the f2/f1 values were 86.8/18.2.
Figure 3-7b2 and 3-7c also showed the effect of V0 (~ 0.2 and 0.27 mL,
respectively) with the constant drug concentration (3%) and fixed surface area.

The effect of C0 and S simultaneously was explored by predicting the drug release
from the formulation 3-1c with different drug concentration (1.5%) in cylinder #6 with
the diameter of 17.5 mm. Figure 3-7d showed the predicted drug release amount by time
and the experimental data. In terms of percentage release, the f2/f1 values were 88.5/7.2.
The effect of C0, V0 and S simultaneously was explored by predicting the drug
release from the formulation 3-1c with the drug concentration (1.5%), loading volume
(0.26 mL), and the cylinder #6 with the different diameter of 17.5 mm. Figure 3-7e
showed the predicted drug release amount by time and the experimental data. In terms of
percentage release, the f2/f1 values were 88.9/8.8.
According to the FDA guidance,111 two dissolution profiles are declared
equivalence if f1 values are between 0 and 15 and f2 value are between 50 and 100. From
aforementioned results, after changing several parameters simultaneously, there is no
significant difference between experimental and predicted data. Therefore Equation 3-9
can give a good prediction of the amount of drug release for the tested formulation and it
is expected that Equation 3-9 can be used to describe the drug release process in CIB
dissolution system.
3.3.3.

IVIVC

Level A IVIVC represents a point-to-point relationship between in vitro
dissolution and the in vivo drug absorption from the tested dosage form. Although there
is the lack of the regulatory IVIVC guidance for parenterals, it is believed that the FDA
principles of the IVIVC for modified solid dosage form can be used for parenterals.107
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Figure 3-7. The buprenorphine release profile and the comparison of
experimental data and predicted data at different conditions.

(a) The initial buprenorphine release profile from formulation 3-1a with concentration of
0.3% and loading volume of ~0.2 mL in the cylinder #5 (diameter: 15 mm).
(b.1) Changing C0 to 1.5%.
(b.2) Changing C0 to 3%.
(c) Changing C0 to 3% and V0 to 0.27 mL.
(d) Changing C0 to 1.5% and using cylinder #6 (diameter: 17.5 mm).
(e) Changing C0 to 1.5%, V0 to 0.26 mL and using cylinder #6 (diameter: 17.5 mm).
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For a reasonable IVIVC, FDA guidance108 states that two or more formulations with
different release rates should be used to demonstrate the IVIVC relationship and the
absolute percentage prediction errors (PE%) of Cmax and AUC should be less than 15%
for each formulation and the average number are less than 10%. If these criteria are not
met, evaluation of external predictability of the IVIVC should be performed.
The in vivo drug release data of formulation 3-1b and 3-2 in rat studies were used
to develop Level A IVIVC. After intravenously administration of buprenorphine solution
at a dose of 0.05 mg/kg, the average values of K10, K12, K21, V1, and AUC of six SD rats
were 1.21 hr-1, 0.82 hr-1, 0.94 hr-1, 764 mL, and 13.2 hr·ng·mL-1 respectively. After
subcutaneous injection of the buprenorphine saline solution at the same dose, the AUC
with the value of 18.4 hr·ng·mL-1 was calculated. After normalizing by dose, the
calculated bioavailability was 116%. The value is more than 100% and this could be
caused by the variance of individual rat. The value 100% of bioavailability was used in
the following calculation. Figure 3-8a shows in vivo drug plasma concentration profile
of formulation 3-1b and 3-2 prepared with TBC and ATBC, respectively. The figure
indicates that drug release rate is different for the two formulations. The drug release
occurred in a controlled manner for two weeks. Buprenorphine solution prepared with
TBC was able to achieve average Cmax of 8.5 ng/mL at 6 hours at the dose of 3 mg/kg
and maintain the average plasma concentrations above 0.96 ng/mL for 336 hours (14
days). Buprenorphine solution prepared with ATBC was able to achieve average Cmax of
11.15 ng/mL at 12 hours at the same dose and maintain the average plasma
concentrations above 1 ng/mL for at least 192 hours (8 days). Also the drug release rate
of Formulation 3-2 was higher than that of Formulation 3-1b.
The IV plasma profile showed the characters of the distribution and elimination
phases, Therefore the Loo-Reigelman method developed from two compartment model
was used to calculate the fraction of drug absorbed in vivo (Fa). Figure 3-8b shows the
in vivo cumulative drug releases after subcutaneous injection of formulation 3-1b and
3-2. The ATBC and TBC formulation displayed different absorption rate. The drug
release from ATBC formulation was faster than that from TBC formulation. Figure 3-8c
indicates a good linear correlation between Ln[C0V0/(C0V0-Mt)] verse time with R2 =
0.9943 for TBC formulation and 0.9979 for ATBC formulation, respectively. It can be
speculated that Equation 3-8 also describes the in vivo drug release after subcutaneous
injection of formulation 3-1b and 3-2.
In vitro dissolution study was conducted with the same formulations (Figure
3-9a). The loading volume of the oily formulation was the same with that in in vivo
study. The principles of media selection will be discussed in Chapter 4. Since the real
time release of tested formulations will last for two weeks, accelerated conditions were
applied in dissolution study with the time scale factor of 2. The dissolution medium of
15% of n- propyl alcohol in PBS (v/v) with 0.15% SDS at pH6.0 was selected and the
paddle speed was set at 100 rpm. A good linear correlation between Ln[C0V0/(C0V0-Mt)]
and time was also obtained with R2 = 0.9966 for TBC formulation and R2 = 0.9991 for
ATBC formulation, respectively (Figure 3-9b). The slopes of the in vivo data were
determined to be about 0.0117 hr-1and 0.00718 hr-1 (Figure 3-8c) for the “fast” and
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Figure 3-8. In vivo data process of formulation 3-1b and 3-2 after subcutaneous
injection in rats for IVIVC development.

(a) Plasma concentration profile of buprenorphine.
(b) In vivo cumulative drug release profile.
(c) Relationship between Ln[C0V0/(C0V0-Mt)] and time after subcutaneous injection of
formulation 3-1b and 3-2 prepared with different oily vehicles in rat study.
Doses of in vivo studies were 3 mg/Kg.
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Figure 3-9. In vitro data process of formulation 3-1b and 3-2 for IVIVC
development.

(a) In vitro drug release profiles.
(b) Relationship between Ln[C0V0/(C0V0-Mt)] and time.
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“slow” release dosage forms, corresponding to the in vitro release slopes of 0.014 hr-1and
0.0098 hr-1 (Figure 3-9b) for the relative formulations. These indicated that the
mechanism of in vitro drug release mimics those of in vivo drug absorption and there
could be a point to point correlation between in vivo and in vitro data.
A level A in-vitro in-vivo correlation was investigated using the percent of drug
dissolved and the percent of drug absorbed data for the slow and fast release
formulations. A good linear regression relationship was observed between the percent
dissolved in the dissolution testing and the percent absorbed for the combined data of the
two formulations (y=1.051x-0.7036, R2 = 0.9918, Figure 3-10).
The validation of the correlation was performed by determining how well the
IVIVC models could predict the rate and extent of buprenorphine absorption as
characterized by Cmax and AUC. The IVIVC model predicted drug plasma concentration
versus time profiles of formulation 3-1b and 3-2 were compared to the experimental data
points. The observed and predicted Cmax, AUC and the percentage errors of internal
validation were listed in Table 3-2. The absolute PE% of Cmax and AUC are less than
15% for each formulation and the average number are less than 10%, which fit the FDA
requirement.
Although it is not required by FDA, formulation 3-3a was used to perform
external validation of the IVIVC model. The dissolution medium and conditions used in
internal validation were applied to perform in vitro dissolution study. Figure 3-11 shows
in vitro drug release profile of formulation 3-3a. It indicates that drug release rate and
release profile of formulation 3-3a are different with those of formulation 3-1b and 3-2
(Figure 3-8b). The IVIVC developed from formulations 3-1b and 3-2 was used to predict
the plasma concentrations of the new formulation. Table 3-3 indicates the
actual/predicted Cmax and AUC are 6.91/7.73 ng mL-1 and 1138.6/1151.4 hr•ng mL-1,
respectively. The absolute PE% of Cmax and AUC are less than 15%. The fraction of
drug absorbed in vivo was also calculated by Loo-Reigelman method (Figure 3-12). In
this case, the fraction of drug absorb in vivo and percentage of drug released in vitro also
showed a good linear relationship (Figure 3-13, R2 = 0.9922).
3.4.

Conclusions

To date it is still a challenge to develop a Level A IVIVC for parenteral products
and there is no standard in vitro dissolution model with the character of Level A IVIVC
for oily formulations. The cylinder-in-basket (CIB) model was designed based on the
drug absorption mechanism after subcutaneous injection. A mathematical equation,
Equation 3-9, was derived to improve the understanding of the diffusion controlled drug
release mechanism involved in the CIB model. The equation was verified by challenging
the parameters in the equation and comparing the experimental drug release data with
predicted data. According to the equation, in vitro drug release follows the 1st order, and
the equation could also describe the in vivo drug release mechanism after subcutaneous
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Figure 3-10. IVIVC model linear regression plots of percent absorbed versus
percent released for formulation 3-1b and 3-2.

%Abs = 1.051·%Released - 0.7036, R2 = 0.9918.
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Table 3-2.

Table 3-3.

Internal predictability of the IVIVC model.
Vehicle

Formulation

TBC
ATBC

3-1b
3-2

Cmax (ng/mL)
Observed Predicted
PE(%)

8.44
11.10

8.85
9.70

4.9
-12.6

AUC (hr*ng/mL)
Observed Predicted PE(%)

1179.2
1307.2

1189.84
1262.50

0.9
-3.4

External predictability of the IVIVC model.
Vehicle

Formulation

TEC:ATEC:TBC
(1:1:1, v/v/v)

3-3a

Cmax (ng/mL)
Observed Predicted
PE(%)

6.91

7.73
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Figure 3-11. In vitro drug release of formulation 3-3a.

n = 3.
Data are presented as mean ± SD.
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Figure 3-12. (a) Plasma concentration profile of buprenorphine, and (b) in vivo
cumulative drug release profile after s.c. injection of formulation 3-3a in rats.

n = 4.
Data are presented as mean ± SD.
Dose of in vivo study is 3 mg/Kg.
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Figure 3-13. Linear regression of percent absorbed versus percent released for
formulation 3-3a.
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injection in rat studies. The results of linear relationship between Fa and Fdiss and
validation results suggested that Level A IVIVC was developed for the tested oily
formations using the CIB model. This is the first time there is an in vitro dissolution
system with the character of level A IVIVC for oily formulations. It also has the potential
to be applied to other parenteral dosage forms if they share the same drug release
mechanism. The Equation 3-9 was derived from diffusion controlled drug release
mechanism and some assumptions were made during the derivation. Therefore all these
should be considered if CIB dissolution model was applied to other dosage forms. In
addition, CIB devices were modified based on the USP apparatus I & II. Therefore it is
easy to be applied in the dissolution labs since USP apparatus I & II are the most popular
dissolution devices and available in the labs. This novel in vitro dissolution model may
contribute as a valuable tool for formulation development, bioequivalence testing, and as
an aid in setting dissolution specifications in QC of parenteral products.
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CHAPTER 4. APPLICATION OF A NOVEL IN VITRO DISSOLUTION
MODEL: A RATIONAL METHOD TO SELECT THE DISSOLUTION
CONDITIONS IN AN ACCELERATED DISSOLUTION STUDY
4.1.

Introduction

Unlike extended release (ER) solid dosage forms, ER parenterals were usually
designed to release drug for days, weeks, months, and even years. The real-time
dissolution analysis of ER parenteral formulations is time-consuming and sometimes
impractical. Accelerated in vitro release study can correlate short-time release data with
real-time release data in order to predict real-time drug release and minimize the potential
problems in the real-time release studies, such as stability. Therefore, accelerated in vitro
release testing methods are important and helpful for quality control of the product and
ER parenteral formulation development.
Usually the problem for accelerated study is that accelerated methods may not be
bio-relevant and often change not only the drug release rate but also the mechanism of
release.70,103 This change may not affect quality control and formulation development of
the ER parenterals, but it could increase the difficulty to establish Level A in vitro-in vivo
correction (IVIVC). In order to increase drug release rate without changing the release
mechanism in the accelerated study, it is very important to choose suitable in vitro
dissolution model and conditions, and understand how the variables affect the drug
release mechanism.
Temperature, solvent, pH, surfactants, agitation rate, etc106,114 have been
successfully applied in the accelerated study to change the drug release rate, but it is
always a challenge, especially for the ER parenterals, to explore the rational method to
find the desired dissolution conditions for in vitro accelerated testing in a short-time
period. Ideally, the accelerated in vitro study should be bio-relevant and correlate with
the in vivo study, especially if the accelerated method is to be used as a surrogate for in
vivo studies.70 In addition, the ideal accelerated condition should only increase the drug
release rate without changing the release mechanism. The Cylinder-in-Basket (CIB)
method has shown bio-relevant with the character of level A IVIVC and discussed in
Chapter 3. The drug release mechanism of CIB model follows the first-order kinetic and
Equation 4-1 is developed to describe in vitro drug release in this model. Equation 4-2
is derived from Equation 4-1 and is used to describe the in vivo drug release of tested
formulations after subcutaneous injection.
For in vitro:

Ln(C0V0 )  Ln(C0V0  M t )  K appt
K app 

DS
KS

hV0 P V0 P
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(Eq. 4-1)

For in vivo:

LnMtotal  Ln( M total  M t )  Kappt

(Eq. 4-2)

where C0 and V0 represent initial drug concentration and volume of loaded formulation;
Mt represents the amount of drug at different time in aqueous phase in in vitro studies and
the amount of drug released at different time point in in vivo studies; D, h and S represent
diffusion coefficient, the length of diffusion layer, and oil-water interface area; the K is
the ratio of D divided by h and Kapp is the apparent rate constant; Mtotal represent the total
amount of drug released at different time point in in vivo studies.
Theoretically, drug release rate, Kapp, should be altered without changing the
release mechanism. Kapp is related to K, S, V0 and P. Therefore it is possible to find a
rational method to select dissolution medium based on the information of Kapp. The
purpose of this study is to apply CIB dissolution model in the accelerated study for
parenterals and develop a rational method to select the accelerated dissolution condition
in a short time period.
4.2.
4.2.1.

Materials and Methods

Materials

Buprenorphine base was obtained from Diosynth Inc. (Morrisville, NC). Tributyl
citrate (TBC), and acetyltributyl citrate (ATBC) were obtained from Morflex, Inc.
(Greensboro, NC).
4.2.2.

Analytical methodology - HPLC/Fluorescence analyses

Validated HPLC method developed to quantitate buprenorphine in the samples
obtained from in vitro studies was described in Chapter 2. Briefly, Discovery C-18
column (2.1 x 100 mm) (Supelco, Bellefonte, PA) was used. The mobile phase was
composed of a mixture of 51 mM KH2PO4 buffer and acetonitrile (ACN) (45:55, v/v)
with the final pH 6.65 adjusted by 10N NaOH solution. The oven temperature was 40°C
and the flow rate was 0.3 mL/min. The total run time was 6 minutes. Buprenorphine was
detected with fluorescence detector at λExitation = 292 nm and λEmission = 350 nm.
4.2.3.

Dissolution method

In vitro dissolution studies of buprenorphine ER formulations were tested in the
cylinder-in-basket (CIB) dissolution model.115 The oily formulation was loaded into the
cavity of the cylinder with the diameter of 15 mm and the height of 24.6 mm. After
covering with the 40-mesh United States Pharmacopeia (USP) basket, the cylinder-in-
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basket kit was transferred to 1-Liter vessel. The 900 mL dissolution medium was
carefully loaded into the vessel at the rate of 7 mL/sec by modified Hanson Media Mate
(Hanson Research Corp.). Different dissolution media were tested for different purposes
and the content of the media will be specified in the following discussion section. The
USP paddle was then loaded on the top of the basket with the distance of 2 cm between
paddle and basket. The vessels were covered with a lid and tightened with laboratory
para-film in order to avoid evaporation of the medium. The experiments were conducted
in triplet. During the experiment, 1 mL of samples was withdrawn from bulk dissolution
medium at predetermined time points by AutoPlus Autosampler (Hanson Research
Corp.). After sampling, 1 mL blank dissolution medium was refilled into the bulk
dissolution medium. Drug content in the samples was measured by HPLC method. The
stability studies were also performed in triplet and conducted at 25 ± 0.5 °C and 40 ± 0.5
°C ovens for tested formulations in all tested dissolution media. The results showed that
buprenorphine was stable in the all dissolution media at 40 ± 0.5 °C for the length of
tested dissolution time.
The amount of drug release in percentage from the oily solutions was calculated
according to Equation 4-2.
n

% released 

Vs   C n1  Vb  C n
n 1

M total

 100%

(Eq. 4-2)

where Vs is the sampling volume (1 mL in this study) at different time points and Vb is
the volume of total dissolution medium. Cn and Cn-1 represent the drug concentration in
sample n and n-1. Mtotal is the total amount of drug in the tested formulation.
4.2.4.

Formulation preparation

In this study, buprenorphine ER oily formulations were used as the model system
and the formulation preparation was described as following. An appropriate amount of
buprenorphine powder was accurately weighed and dispersed into an appropriate amount
of solvent (Table 4-1) in 20 mL glass scintillation vials. The subsequent suspension was
sonicated under 25ºC until all drug powder was dissolved. The drug concentration was
verified by HPLC method. The formulation 4-1 and 4-2 have the same composition as
formulation 3-2 and 3-1b, respectively.
4.2.5.

Partition coefficients

The partition coefficient testing of buprenorphine between the oily vehicles and
dissolution media was performed in triplicate. Solutions of drug in aqueous phasesaturated oily vehicles were allowed to equilibrate with the oil phase-saturated aqueous
buffers in the incubator at 100 rpm and 37 ± 0.5°C for at least 48 hr. Drug concentrations
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Table 4-1.
Formulations tested in the method development of accelerated
dissolution study.
Formulation

Solvent

4-1
4-2

ATBC
TBC

Concentration of Buprenorphine in Solvent
% (w/w)
0.5
0.5
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in the aqueous phase and oily phase were determined by HPLC method. The partition
coefficients were calculated according to Equation 3-1.
P

C oil
C aq

(Eq. 3-1)

where Coil and Caq represent the drug concentration in the oil and the aqueous phase at the
equilibrium state, respectively.
4.3.

Results and Discussion

Dissolution temperature and medium are two major conditions altered in the
accelerated in vitro study. Dr. Burgess stated that elevated temperature in accelerated
release testing was not suitable for PLGA microsphere systems in which release
mechanism was diffusion controlled.116 It is speculated that elevated temperature may not
be suitable for oily formulation in the accelerated study since it shared the same diffusion
controlled release mechanism. Therefore one of the common parameters, temperature,
was not selected to explore in this accelerated study. The altered pH and different amount
of surfactant in the dissolution medium can accelerate the drug release rate and the effects
of these parameters were explored in this study using CIB in vitro dissolution model.
The pH effect of dissolution medium was firstly explored using USP buffer with
pH 7.4, 6.8, 6.0 and 5.0. The release of buprenorphine from formulation 4-1 and 4-2 in
different oily vehicles, ATBC and TBC, was tested. The cylinder with the diameter of 15
mm and the height of 24.6 mm was used in this study. Figure 4-1 shows the drug release
effect of the dissolution medium with different pH. The partition coefficients between
different oily phases and dissolution media were also tested and the results are listed in
Table 4-2. Buprenorphine is a weak base. When pH of the dissolution media changed,
the ionization extent of drug will change, therefore solubility of drug in the dissolution
media and the partition coefficient between oily phase and media will also vary. When
the pH of dissolution medium changed from 7.4 to 5, the drug release rate increases and
the partition coefficient decreases.
Equation 4-1 described the drug release in the USP phosphate buffer with the pH
of 6, 6.8 and 7.4 and the linear relationship (R2 > 0.99, Table 4-2) was obtained after
plotting Ln[C0V0/(C0V0-Mt)] versus time. This indicated when pH of the dissolution
media changed from 7.4 to 6.0, the drug release could be described by the same equation
and the release mechanism does not change. It followed 1st-order release for the tested
formulations and could be applied in the accelerated studies since the release rate could
be increased without changing the release mechanism. Unfortunately, good linear
relationship was not observed when applying pH 5.0 USP neutralized phthalate buffer
(R2 = 0.9603 for formulation 4-1; R2 = 0.948 for formulation 4-2). The reason could be
that pH effect or the drug release behavior in phthalate buffer solution (USP buffer, pH 5)
may be different with that in phosphate solutions (USP buffer, pH 6, 6.8 and 7.4).
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In vitro release of buprenorphine from TBC formulation
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Figure 4-1. In vitro drug release profiles from (a) formulation 4-1 and (b)
formulation 4-2 in USP specified dissolution media at different pH.

n =3.
Data are presented as mean ± SD.
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Table 4-2.

Dissolution paddle speed, partition coefficient and calculated parameters in accelerated studies.

Dissolution Medium
USP buffer pH 7.4
USP buffer pH 6.8
USP buffer pH 6.0
USP buffer pH 5.0
PBS with 0.05% (w/v) SDS at pH 6
PBS with 0.1% (w/v) SDS at pH 6
PBS with 0.8% (w/v) SDS at pH 6
PBS with 0.1% (w/v) SDS at pH 7.4
PBS with 0.2% (w/v) SDS at pH 7.4
PBS with 0.8% (w/v) SDS at pH 7.4

Paddle
Speed
(rpm)
50
50
50
50
50
50
50
150
150
150

Formulation 4-1
(Oily Phase: ATBC)
Kapp
K
R2
P
(hr-1)
(cm/hr)
8992.7 ± 323.1
2129.1 ± 75.5
403.2 ± 26.9
35.6 ± 1.6
139.6 ± 29.5
47.4 ± 1.6
2.5 ± 0.1
233.6 ± 7.2
43.1 ± 2.3
28.9 ± 4.0

0.0010
0.0034
0.0082
0.1117
0.0269
0.0831
0.4019
0.0485
0.7732
1.2097

0.9951
0.9946
0.9913
0.9603
0.9910
0.9938
0.8557
0.9994
0.9904
0.9904

1.094
0.8806
0.4022
NA
0.4501
0.4567
NA
1.34
3.83
2.94

P

Formulation 4-2
(Oily Phase: TBC)
Kapp
K
R2
-1
(hr )
(cm/hr)

1953.9 ± 110.7
564.5 ± 3.8
151.7 ± 12.7
64.8 ± 2.1
756.5 ± 35.2
331.5 ± 8.5
16.1 ± 0.6
3979.5 ± 89.0
324.6 ± 5.5
31.2 ± 3.3

0.0008
0.0029
0.005
0.0923
0.0084
0.0201
0.4679
0.0119
0.0957
0.6876

PBS: phosphate buffer saline solution
NA: not accessed
Kapp and R2 were obtained by plotting Ln[C0V0/(C0V0-Mt)] versus time and K was calculated from Equation 4-1.
n =3.
Data of partition coefficient (P) are presented as mean ± SD.
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0.9937
0.9934
0.9933
0.9480
0.9901
0.9997
0.9829
0.9978
0.9940
0.9997

0.1853
0.1941
0.0773
NA
0.7525
0.769
0.874
5.43
3.53
2.45

The ideal accelerated condition should increase drug release rate without
changing the drug release mechanism. According to Equation 4-1, the apparent drug
release rate, Kapp, is related with the parameters of K, S, V0 and P. Amongst four
parameters, S and V0 are considered as the constant for the selected cylinder and loading
volume. Diffusion transportation is affected by agitation, medium viscosity and medium
temperature.117 Agitation could affect the thickness of diffusion layer, h. According to the
Stokes-Einstein equation, D is related to solvent viscosity, temperature and solute
molecule radius. For the given drug molecule, oily vehicle, dissolution medium,
temperature and pressure, the D could be considered as the constant. The change of
dissolution medium would simultaneously change h and P between oil phase and media,
therefore the K value will vary. In the accelerated testing, temperature, dissolution
medium, and/or agitation speed has to be the parameters used to accelerate the drug
release rate. Both values of K and P will always vary simultaneously in these situations.
It seems impractical to apply Equation 4-1 to select accelerated condition since none of
the two variables, P and K, is the constant for different dissolution media.
But the question is when altered dissolution medium is used to increase
dissolution rate, such as pH or amount of surfactant in the medium, how does the K value
vary? Table 4-2 lists the experimental K values for tested formulations in the dissolution
medium with different pH. When pH is changed from 7.4 to 6.0, the P values decrease
22.3 and 30.2 folds for two formulations, respectively, while the K values decrease 2.7
and 2.4 folds, respectively. This indicates that the variance of P is much larger than that
of K. Therefore, if the P values have just “slightly difference”, the variance of K value
could be rounded and considered as a constant. If K can be considered as the constant, it
gives the possibility to select dissolution medium with desired drug release rate just from
tested P values between oily vehicles and dissolution media.
The assumption, “if the P values have just slightly difference, the variance of K
value could be rounded and considered as a constant”, is made here. When it is validated,
it will be helpful to choose dissolution medium based on the P values in the accelerated
study. The procedures (Figure 4-2) of selecting dissolution medium in accelerated
studies were listed as following.
1. Calculate slopereal-time. The CIB dissolution model displays the character of
Level A IVIVC for the oily formulations. Therefore the in vivo fraction of drug
absorbed (Fa) profiles were applied as the real-time in vitro dissolution release
profiles since Level A IVIVC has been established for the tested
formulations.115 Plot real-time in vivo release profile of long term sustained
release oily formulation from in vivo data and calculate slopereal-time by plotting
Ln[Mtotal/(Mtotal-Mt)] versus time. The value slopereal-time is calculated from in
vivo data and considered as the real-time slope of in vitro release.
2. Select time scale factor.
3. Select the type of cylinder and calculate S.
4. Decide the loading volume (V0) for in vitro testing. For IVIVC purpose, the
recommended loading volume is to keep the same volume used for in vivo
study.
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Select initial dissolution
medium and cylinder, start
initial in vitro dissolution
study and calculate K
(Equation 4-4)

Calculate slopereal-time

Select time scale factor and
calculate recommended P
(Equation 4-6)

Measure a series of P values
by varying the conditions in
the dissolution media

Select desired dissolution
medium based on P value
and calculate K

No
Use new K

Ratio of K
Close to 1?
Yes

New in vitro dissolution test
with desired release rate

Figure 4-2.

The procedures of selecting dissolution medium in accelerated study.
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5. Run the initial in vitro dissolution test using the CIB dissolution model and
calculate the K value by plotting Ln[C0V0/(C0V0-Mt)] versus time. Since there
is no information about the dissolution media, the initial dissolution can be
selected based on the experience or other criteria.
6. Calculate recommended P value according to the following Equation 4-6.
7. Measure a series of P values by varying the conditions in the dissolution media.
For example, select different amount of surfactant to increase the drug release
rate.
8. Select second dissolution medium based on the recommended P value and run
second in vitro experiment to verify the results.
9. Calculate new K value from second dissolution study by plotting
Ln[C0V0/(C0V0-Mt)] versus time. If the ratio of P values between oil/initial
medium and oil/second medium has significant difference or K values are not
close to 1, the new K value can be used to calculate the recommended P and
select third dissolution medium. Although third dissolution may be performed,
it will be the last dissolution study since second dissolution study has narrow
down the variance of K.
Accelerated study should not change the drug release mechanism and ideally the
drug release data in accelerated study can correlate with in vivo drug absorption data.
With this assumption, in vivo fraction of drug absorbed (Fa) profile could be considered
as the ideal real-time in vitro drug release profile. Unfortunately the IVIVC for
parenterals is always the challenge. Chapter 2 demonstrated that novel cylinder-inbasket (CIB) in vitro dissolution model has the character of level A IVIVC for parenteral
oily formulations. So in this study in vivo drug absorption profiles of tested formulations
were used as the real-time in vitro drug release dissolution profiles. All the in vitro
dissolution data generated were then compared with the real-time in vitro dissolution
profiles in this study and relationship between accelerated in vitro release data and realtime release data were described by Equation 4-3.
Slopein vitro = Slopereal-time· time scale factor = Slopein vivo· time scale factor

(Eq. 4-3)

The slopein vitro is calculated by plotting Ln[C0V0/(C0V0-Mt)] verse time using in
vitro dissolution data and the slopein vitro (Kapp), coefficient of determination (R2) and K
were listed in Table 4-2. The slope of the in vivo profile (Slopein vivo) by plotting
Ln[Mtotal/(Mtotal-Mt)] verse time follows the first order kinetics and equals to the sloperealtime when the time scale factor is one. In this study, the bioavailability of the tested
formulations equals to 100% (chapter 2). Therefore Mtotal equals to the amount of drug
injected.
From Equation 4-1 and 4-3, parameters of K, time scale factor and P can be
calculated by Equations 4-4, 4-5 and 4-6, respectively.
Slope in vitro  Slope real - time  Time scale factor  K app 
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KS
V0 P

K

K app V0 P
S

K app
Slope real - time
KS
P
V0  Slopereal-time  Time scale factor

Time scale factor 

(Eq. 4-4)
(Eq. 4-5)
(Eq. 4-6)

The following two cases will discuss how this rational method is applied to select
dissolution medium in which desired drug release rate can achieve.
4.3.1.

Case studies

4.3.1.1. Case 1 (Formulation 4-1, time scale factor = 7)

More than 90% of drug was released from formulation 4-1 within two weeks
(Figure 3-9a). Chapter 3 discussed Level A IVIVC is exist in this dissolution model for
the tested formulations. Therefore in vivo percentage of drug absorption of formulation
4-1 (Figure 3-9b) is considered as the ideal in vitro drug release profile. In order to
accelerate the in vitro drug release rate of the formulation, time scale factor 7 is applied
and the whole process can be described by two steps.
Step 1: calculation of parameter K. In the preliminary study, the solubility of
buprenorphine in the medium with either non-ionic (Tween 80; Span 80) or ionic
(Sodium Dodecyl Sulfate, SDS) surfactant are tested. The solubility of buprenorphine in
8% (v/v) Tween 80 in PBS at pH 7.4 and 8% Span 80 (v/v) in PBS at pH 7.4 are less than
35 μg/mL, while the solubility of buprenorphine in PBS with 0.05% SDS (w/v) at pH 7.4
is 43.8 μg/mL. In order to keep the sink condition, the solubility of the buprenorphine in
the dissolution medium is desired to be more than 35 μg/mL. Higher amount of non-ionic
surfactant may also cause larger variation and has less flexibility to adjust in the future
study, so surfactant SDS is used in the study to increase the solubility and maintain the
sink condition in this study. The experimental Kapp equals to 0.0269 hr-1 when the
formulation 4-1 is diffused into the medium of PBS with 0.05% (w/v) SDS at pH 6
(Table 4-2). The cylinder with the diameter of 15 mm was used in this study and the
loading volume (V0) of 0.2 mL was kept the same with the in vivo study. The
experimental P equals to 139.6. Therefore, useful parameter K can also be calculated and
the value is 0.4501 cm/hr.
Step 2: dissolution medium selection based on tested P value. It is possible to
select the medium with desired P and achieve the objective if all the parameters in
Equation 4-6 are available. The aforementioned assumption is if the variance of P is
ignorable, the K could be considered as a constant to anticipate the P of the desired
dissolution medium. In this case, the calculated K is around 0.45 cm/hr and the calculated
P value is 48.5 from Equation 4-6 with the time scale factor of 7. After testing a series of

93

partition coefficients between ATBC and PBS solution at pH 6 with different amount of
SDS, the medium of PBS with 0.1% (w/v) SDS at pH 6 was selected to do further
dissolution test since tested P is 47 which is very close to estimated value of 48.5. And
the ratio 3.34 of two P values (139.6 / 41.7) is considered as the acceptable variance. The
used cylinder has the diameter of 15 mm and the loading volume of 0.2 mL was kept the
same with the in vivo study. Figure 4-3a indicates the experimental and real-time amount
of drug release data. The x axis is the real-time divided by time scale factor. Figure 4-3b
shows that the relationship between accelerated drug release data (%releasedin vitro (y) )
and real-time drug release data divided by time scale factor (%releasedreal-time (x)) can be
described by the linear equation: y = 1.0509x+0.4309 (R2 = 0.9987). It indicates that the
accelerated drug release amount of formulation 4-1 in CIB model can be predicted and a
good IVIVC between in vivo drug release and accelerated experimental data is
established.
4.3.2.2. Case 2 (Formulation 4-2, time scale factor = 14)

In vivo drug release of formulation 4-2 can also last two weeks (Figure 3-9a) and
in vivo percentage of drug absorption of formulation 4-2 (Figure 3-9b) is considered as
the ideal in vitro drug release profile. In order to accelerate the in vitro drug release rate
of the formulation, time scale factor 14 is applied and the whole process can be described
by two steps.
Step 1: calculation of K. In order to validate aforementioned method, formulation
4-2 was tested at different conditions. The first in vitro dissolution test was performed at
150 rpm in the PBS medium with 0.1% (w/v) SDS at pH 7.4. The experimental P value
of buprenorphine between TBC and dissolution medium is 3979.5. The cylinder with the
diameter of 15 mm and the loading volume (V0) of 0.2 mL were kept the same with the in
vivo study. After plotting Ln[C0V0/(C0V0-Mt)] verse time, the Kapp value is 0.0119 hr-1
with R2 of 0.9978. Therefore the calculated K is 5.43 cm/hr (Table 4-2).
Step 2: selection of dissolution medium based on tested P value. The sustained
release formulation 4-2 can release more than 90% drug molecules in rats within 14
days.115 According to Equation 4-2, the slopein vivo of the formulation is 0.00718 hr-1.
When time scale factor 14 is applied, the recommended P is 479.74 calculated from
Equation 4-6. After testing a series of partition coefficients between TBC and PBS
solution at pH 7.4 with different amount of SDS, the medium of PBS with 0.2% (w/v)
SDS at pH 7.4 was selected to do further dissolution test since experimental P is 325
which is close to estimated value. After analyzing the results from the dissolution study,
K value from the new dissolution medium is calculated and the value is 3.53 which is not
close to the initial K value of 5.43. The reason is that the change of the P values between
the two dissolution media (from 3979.5 to 324.6) is beyond the limit of the assumption.
Therefore the new recommended P should be calculated from the new K value, 3.53. The
second recommended P is calculated from the new dissolution results and the P value is
318 which is close to the previous tested value of 325. Otherwise, new dissolution
medium should be selected based on the tested P values and the third dissolution test
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4-1.
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should be run and will give desired drug release profile. Figure 4-4a indicates the
experimental and real-time amount of drug release. The x-axis is the dissolution time for
in vitro study and real-time divided by time scale factor for in vivo study. Figure 4-4b
shows that the linear equation, y = 0.9722x+4.8577 (R2 = 0.9931), can describe the
relationship between drug release data in accelerated study (%releasedin vitro (y)) and realtime drug release data (%releasedreal-time (x)) by applying time scale factor. It also
indicates that a good IVIVC has been established and the drug release amount from
formulation 4-2 at different time points in CIB model can be predicted.
4.3.2.

Discussion

This study presented a rational method to select dissolution medium by testing
just one or two in vitro dissolution experiments and measuring the partition coefficients
between oily phase and different dissolution media. The initial in vitro dissolution
experiment is to calculate K value of the initial dissolution system and obtain desired P
value. The desired dissolution medium can be selected based on this P value. The above
two cases indicate that the rational method has been developed and established to find the
desired dissolution medium.
The assumption of the method is “slightly difference” between the P values and K
is considered as the constant by changing the content of the medium. In the 2nd case, the
ratio of P values between oil/initial medium and oil/selected medium is 12.3 folds. The
predicted P is 400.8 and the experimental P value between TBC and selected medium is
325. The tested K values for the two media are close (4.56 vs 3.53, Table 4-2) but can’t
be rounded. In this case, an additional dissolution experiment may be required to
precisely predict P if ratio of P values between oil/initial medium and oil/selected
medium is too high, or predicted accelerated data does not match the experimental data. It
is difficult to define a constant value of P ratio to be the boundary so far. From author’s
opinion, comparing K values may be more practical. If the ratio of K is close to 1, only
one dissolution experiment can give a good or reasonable prediction. If not, extra
attention should be paid and the calculated new K value from 2nd dissolution medium
could be used to calculate new recommended K. The same procedure can be applied
again to select dissolution medium. The new dissolution experiment actually refined the
dissolution condition. General after maximum two dissolution tests the desired
dissolution medium could be found. It is recommended the ratio of K values should
always be examined.
The real-time drug release from formulation 4-1 and 4-2 can last for 14 days. The
aforementioned two cases gave the examples how to select the dissolution medium by a
rational method to achieve drug release within 2 and 1 day, respectively, without
changing the release mechanism. Ideally, shorter dissolution time, such as couple of
hours, is preferred in accelerated study to provide the drug release information of the 14
days sustained release formulation, and it will accelerate the formulation development
and benefit QC. Theoretically it seems possible to achieve the objective since high
amount of surfactant and/or low pH of dissolution medium could increase the drug
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release rate. Therefore drug release studies in phosphate buffer saline solutions (PBS)
with high amount of surfactant at different pH were performed. The drug release of
formulation 4-1 and 4-2 in PBS with 0.05%, 0.1% or 0.8% SDS (w/v) at pH 6 (50 rpm,
Figure 4-5) and with 0.1, 0.2 or 0.8% SDS (w/v) at pH 7.4 (150 rpm, Figure 4-6) were
invested. The experiments were performed in triplet. Figure 4-5 and 4-6 indicate that
drug release rate increased with the high amount of surfactant in the tested formulations.
Good linear relationship (R2 > 0.98, Table 4-2) was obtained in all dissolution media
except in the PBS medium with 0.8% SDS (w/v) at pH 6 (R2 = 0.856 for formulation 41). High amount of surfactant (0.8% SDS) in the dissolution medium not only
dramatically increased the drug release rate, but also caused the large variance (SD,
~20%) for certain formulation. During the procedure of loading dissolution medium, it is
inevitable to cause some variance when two liquid phases are contacting to each other.
Tiny variance between different vessels could be amplified when the drug release rate is
significantly increased. This indicates that time scale factor should be carefully selected
in order to reduce the variance. The faster release rate, the more variance may get.
4.4.

Conclusions

Accelerated dissolution testing of buprenorphine oily sustained release
formulations was attained by varying the pH and the amount of the surfactant in the
dissolution medium in CIB dissolution model. This study demonstrated that dissolution
of oily formulations in USP phosphate buffer with the pH from 6 to 7.4 followed 1st-order
kinetic and could be described by Equation 4-1. A rational method (Figure 4-2) was
developed in this study to select dissolution medium in the accelerated study according to
the practical requirement. The two cases of 14-day sustained release formulations
demonstrated how to utilize this method to select dissolution medium to achieve desired
in vitro drug release rate without changing drug release mechanism. The proposed
method
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Data are presented as mean ± SD.
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